

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Coleman, MP; Forman, D; Bryant, H; Butler, J; Rachet, B; Maringe, C; Nur, U; Tracey, E; Coory, M; Hatcher, J; +16 more... McGahan, CE; Turner, D; Marrett, L; Gjerstorff, ML; Johannesen, TB; Adolfsson, J; Lambe, M; Lawrence, G; Meechan, D; Morris, EJ; Middleton, R; Steward, J; Richards, MA; ICBP Module 1 Working Group (, inc; Walters, S; ); (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet*, 377 (9760). pp. 127-38. ISSN 0140-6736 DOI: [https://doi.org/10.1016/S0140-6736\(10\)62231-3](https://doi.org/10.1016/S0140-6736(10)62231-3)

Downloaded from: <http://researchonline.lshtm.ac.uk/1857/>

DOI: [https://doi.org/10.1016/S0140-6736\(10\)62231-3](https://doi.org/10.1016/S0140-6736(10)62231-3)

**Usage Guidelines:**

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

# THE LANCET

## **Supplementary webappendix**

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet* 2010; published online Dec 22. DOI:10.1016/S0140-6736(10)62231-3

## **Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data**

**Programme Board:** Ole Andersen (National Board of Health, Health Planning Division, Copenhagen, Denmark); Heather Bryant (Canadian Partnership Against Cancer, Toronto ON, Canada); David Currow (Cancer Institute NSW, Sydney NSW, Australia); Anna Gavin (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Gunilla Gunnarsson (Swedish Association of Local Authorities and Regions, Stockholm, Sweden); Jane Hanson (Cancer Services Co-ordinating Group, Cardiff, Wales, UK); David Hill (Cancer Council Victoria, Melbourne VIC, Australia); Stein Kaasa (University Hospital of Trondheim, Trondheim, Norway); Lone de Neergaard (National Board of Health, Health Planning Division, Copenhagen, Denmark); Michael A Richards (National Cancer Action Team, Department of Health, London, UK; Chair); Terry Sullivan (Cancer Care Ontario, Toronto ON, Canada); **Module 1 leaders:** Jan Adolfsson (Karolinska University Hospital, Stockholm, Sweden); Heather Bryant (Canadian Partnership Against Cancer, Toronto ON, Canada); Michael Coory (Cancer Council Victoria, Melbourne VIC, Australia); David Forman (International Agency for Research on Cancer, Lyon, France; Chair); Marianne L Gjerstorff (Danish Cancer Registry, National Board of Health, Copenhagen, Denmark); Tom Borge Johannesen (Norwegian Cancer Registry, Oslo, Norway); Mats Lambe (Regional Oncological Centre, Uppsala University Hospital, Uppsala, and Karolinska Institutet, Stockholm, Sweden); David Meechan (Trent Cancer Registry, Sheffield, UK); Richard Middleton (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Janey Shin (Canadian Partnership Against Cancer, Toronto ON, Canada); John Steward (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, Wales, UK); Elizabeth Tracey (Cancer Institute NSW, Sydney NSW, Australia); **Cancer registries:** Juanita Hatcher, Carol Russell (Alberta Health Services, Edmonton AB, Canada); Andy Coldman, Mark Elwood, David Levy, Colleen E McGahan (British Columbia Cancer Agency, Vancouver BC, Canada); Dhali Dhaliwal, Donna Turner (CancerCare Manitoba, Winnipeg MB, Canada); Loraine Marrett, John McLaughlin, Kamini Milnes, Diane Nishri, Michael Sherar (Cancer Care Ontario, Toronto ON, Canada); Gerda Engholm (Department of Cancer Prevention and Documentation, Danish Cancer Society, Copenhagen, Denmark); Eva Morris, James Thomas (Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Karen Linklater (Thames Cancer Registry, London, UK); Rebecca Elleray, David Meechan, Andy Smith (Trent Cancer Registry); Gill Lawrence (West Midlands Cancer Intelligence Unit, Birmingham, UK); Finian Bannon, Colin Fox (Northern Ireland Cancer Registry, Belfast, Northern Ireland, UK); Ceri White (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, Wales, UK); **Clinical Committee:** Jonas Bergh (Karolinska Institutet, Stockholm, Sweden); John Boyages (Westmead Breast Cancer Institute, Sydney NSW, Australia); Michel Boyer (Sydney Cancer Centre, Sydney NSW, Australia); John Butler (Department of Health, London, UK); Peter Clark (Clatterbridge Centre for Oncology, Liverpool, UK); Bill Evans (Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, Toronto ON, Canada); Hilary Fielder (Velindre NHS Trust, Cardiff, Wales, UK); Tony Fields (Alberta Health Services, Edmonton AB, Canada); Paul Finan (Leeds Teaching Hospitals NHS Trust, Leeds, UK); Tommy Fornander (Södersjukhuset, Stockholm, Sweden); Neville Hacker (University of New South Wales and Royal Hospital for Women, Sydney NSW, Australia); Louise Hanna (Velindre NHS Trust, Cardiff, Wales, UK); Thomas Hogberg (Skåne University Hospital, Lund, Sweden); Charlotte Hosbond (National Board of Health, Copenhagen, Denmark); Karl Kölbeck (Karolinska University Hospital, Stockholm, Sweden); Martin Lee (University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK); Peter Barrett Lee (Velindre NHS Trust, Cardiff, Wales, UK); Jason Lester (Velindre NHS Trust, Cardiff, Wales, UK); Mark Levine (McMaster University, Hamilton ON, Canada); Gudrun Lindmark (Skåne University Hospital, Malmö-Lund, Sweden); Tim Maughan (Velindre NHS Trust, Cardiff, Wales, UK); Usha Menon (University College London, London, UK); Ian Money Penny (Cardiff & Vale NHS Trust, Cardiff, Wales, UK); Andy Nordin (East Kent University Hospitals, Canterbury, UK); Julietta Patnick (NHS Cancer Screening, Sheffield, UK); Mick Peake (NHS Cancer Improvement, National Cancer Intelligence Network, Department of Respiratory Medicine, Leicester, UK); Andrew Radcliffe (Llandough Hospital, Penarth, Wales, UK); Barry Rosen (University of Toronto, Toronto ON, Canada); Annika Sjövall (Karolinska University Hospital, Stockholm, Sweden); Allan Spigelman (University of New South Wales, Sydney NSW, Australia); Gunnar Wagenius (Uppsala University Hospital, Uppsala, Sweden); Fredrik Wärnberg (Uppsala University Hospital, Uppsala, Sweden); Michael Williams (Addenbrooke's, Cambridge, UK); Ian Williamson (Royal Gwent Hospital, Newport, Wales, UK); **Central Analytic Team (Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK):** Claudia Allemani (also Analytical Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Michel P Coleman, Libby Ellis, Camille Maringe, Ula Nur, Manuela Quaresma, Bernard Rachet, Sarah Walters.

### **Correspondence**

MP Coleman, Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

T +44 20 7612 7849, F +44 20 7436 4230, [michel.coleman@lshtm.ac.uk](mailto:michel.coleman@lshtm.ac.uk)

## Additional references

1. National Board of Health. National Cancer Plan II - Denmark. Copenhagen, Denmark, National Board of Health, 1 June 2005.
2. Cancer Working Group. Cancer Services - Investing for the Future (The Campbell Report). Belfast, Department of Health and Social Services, 1996.
3. Department of Health. The NHS Cancer Plan. London, Department of Health, 2000.
4. Department of Health. Cancer Reform Strategy. London, Department of Health, June 2007.
5. Cancer Services Co-ordinating Group. Designed to Tackle Cancer in Wales: A Welsh Assembly Government Policy Statement. Welsh Assembly Government, December 2006.  
[http://www.wales.nhs.uk/sites3/Documents/322/D2TC\\_Strategic\\_Framework\\_2008-11.pdf](http://www.wales.nhs.uk/sites3/Documents/322/D2TC_Strategic_Framework_2008-11.pdf)
6. Department of Human Services. Victoria's Cancer Action Plan 2008-2011. Melbourne, Victoria, Victorian Government Department of Human Services, 2008.
7. Anon. National Cancer Strategy 2006-2009. Oslo, Norway, Ministry of Health and Care Services, 2010.  
[http://www.regjeringen.no/upload/kilde/hod/anb/2006/0020/ddd/pdfv/296675-kreftstrategien\\_eng\\_25102006\\_kjb.pdf](http://www.regjeringen.no/upload/kilde/hod/anb/2006/0020/ddd/pdfv/296675-kreftstrategien_eng_25102006_kjb.pdf)
8. Ekos Research Associates. Canadian Partnership Against Cancer Corporation: evaluation. Final report: executive summary. Ottawa ON, Health Canada, 6 May 2010. <http://www.partnershipagainstcancer.ca/wp-content/uploads/CPACC-Evaluation-Executive-Summary.pdf>
9. Commission of Inquiry on a National Cancer Strategy. A national cancer strategy for the future. Swedish Government Official Reports SOU 2009:11. Stockholm, Sweden, Swedish Government Inquiries, 2009.  
<http://www.regeringen.se/content/1/c6/12/09/76/01389b21.pdf>

## Webappendix tables and figures

### Exclusion tables

**Webtable 1:** Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **colorectal cancer** (1 page)

**Webtable 2:** Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **lung cancer** (1 page)

**Webtable 3:** Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: **breast cancer (women)** (1 page)

**Webtable 4:** Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions (except Swedish regions) combined: **ovarian cancer** (1 page)

### Number of patients

**Webtable 5:** Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: **colorectal cancer** (2 pages)

**Webtable 6:** Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: **lung cancer** (2 pages)

**Webtable 7:** Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, country and jurisdiction: **breast cancer (women)** (2 pages)

**Webtable 8:** Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, country and jurisdiction: **ovarian cancer** (2 pages)

### Age at diagnosis

**Webtable 9:** Mean age at diagnosis: cancer, jurisdiction and calendar period of diagnosis (1 page)

### Second and higher-order primary

**Webtable 10:** Number and percentage of adults (15-99 years) diagnosed during 1995-2007 whose cancer was a second or higher-order primary: by cancer and jurisdiction (1 page)

### Patients dying within a month

**Webtable 11:** Number and percentage of patients dying within a month of diagnosis, by period of diagnosis and jurisdiction (1 page)

## **Survival by age and calendar period of diagnosis**

**Webtable 12:** Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **cohort analysis for 1995-99** (2 pages)

**Webtable 13:** Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **cohort analysis for 2000-02** (2 pages)

**Webtable 14:** Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, **period analysis for 2005-07** (2 pages)

## **Incidence and mortality**

**Webtable 15:** Age-standardised (world) annual incidence and mortality rates per 100,000 in 2000, with mortality-incidence ratios: cancer and country (1 page)

## **Annex figures**

### **Incidence and mortality trends**

**Incidence and mortality trends 1985-2005: three-year moving average world-standardised rates per 100,000 per year** (1 page)

Notes: Incidence data for Canada exclude Quebec; colorectal cancer includes cancers of the anus and anal canal; lung cancer includes cancers of the trachea. Mortality data labelled UK are for England and Wales only

**Webfigure 1 – Ovarian cancer, incidence**

**Webfigure 2 – Lung cancer, incidence, males**

**Webfigure 3 – Lung cancer, incidence, females**

**Webfigure 4 – Ovarian cancer, mortality**

**Webfigure 5 – Lung cancer, mortality, males**

**Webfigure 6 – Lung cancer, mortality, females**

## **Available on request**

### **Exclusion tables**

**Annex Table 1:** Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007): by cancer and jurisdiction (47 pages)

### **Survival by age and calendar period of diagnosis**

**Annex Table 2:** One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years) diagnosed with cancer during 1995-99: by cancer, age, sex, country and jurisdiction (14 pages)

**Annex Table 3:** One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years) diagnosed with cancer during 2000-02: by cancer, age, sex, country and jurisdiction (14 pages)

**Annex Table 4:** One-year, five-year and conditional five-year relative survival (%), with 95% confidence intervals (CI), for adults (15-99 years), period analysis for 2005-07: by cancer, age, sex, country and jurisdiction (14 pages)

**Table 1: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: colorectal cancer**

	1995-96			1997-98			1999-2000			2001-02		
<b>Total registered</b>	<b>109,281</b>	<b>108,046</b>	<b>100.0</b>	<b>117,134</b>	<b>115,752</b>	<b>100.0</b>	<b>122,127</b>	<b>120,631</b>	<b>100.0</b>	<b>122,529</b>	<b>120,970</b>	<b>100.0</b>
<b>Ineligible</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>
Incomplete data	61	61	<0.1	37	37	<0.1	33	33	<0.1	12	12	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	391	356	0.3	553	497	0.4	712	649	0.5	1,082	1,016	0.8
Benign or uncertain	3,125	2,477	2.3	3,898	3,160	2.7	4,706	3,902	3.2	4,274	3,429	2.8
Metastatic	50	50	<0.1	49	49	<0.1	62	62	<0.1	62	62	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	23	22	<0.1	32	32	<0.1	25	25	<0.1	19	19	<0.1
Leukaemia or myeloma	7	7	<0.1	0	0	0.0	0	0	0.0	0	0	0.0
<b>Total ineligible</b>		<b>2,973</b>	<b>2.8</b>		<b>3,775</b>	<b>3.3</b>		<b>4,671</b>	<b>3.9</b>		<b>4,538</b>	<b>3.8</b>
<b>Total eligible</b>		<b>105,073</b>	<b>100.0</b>		<b>111,977</b>	<b>100.0</b>		<b>115,960</b>	<b>100.0</b>		<b>116,432</b>	<b>100.0</b>
Aged 100+	28	28	<0.1	38	38	<0.1	39	39	<0.1	39	39	<0.1
Vital status unknown	182	124	0.1	156	121	0.1	208	176	0.2	149	139	0.1
Sex not known	1	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	8	7	<0.1	9	8	<0.1	22	21	<0.1	37	35	<0.1
Death certificate only	3,797	3,772	3.6	3,727	3,692	3.3	2,986	2,960	2.6	2,220	2,209	1.9
Autopsy only	161	155	0.1	134	131	0.1	121	119	0.1	94	91	<0.1
Synchronous tumours	595	296	0.3	683	337	0.3	1,051	767	0.7	692	413	0.4
Multiple primary same site	544	142	0.1	837	365	0.3	967	473	0.4	1,087	573	0.5
<b>Total exclusions</b>		<b>4,524</b>	<b>4.3</b>		<b>4,692</b>	<b>4.2</b>		<b>4,555</b>	<b>3.9</b>		<b>3,499</b>	<b>3.0</b>
<b>Patients available for analyses</b>		<b>100,549</b>	<b>95.7</b>		<b>107,285</b>	<b>95.8</b>		<b>111,405</b>	<b>96.1</b>		<b>112,933</b>	<b>97.0</b>

	2003-04			2005-06			2007			1995-2007		
<b>Total registered</b>	<b>126,967</b>	<b>125,035</b>	<b>100.0</b>	<b>133,227</b>	<b>131,144</b>	<b>100.0</b>	<b>68,301</b>	<b>67,483</b>	<b>100.0</b>	<b>799,566</b>	<b>789,061</b>	<b>100.0</b>
<b>Ineligible</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>
Incomplete data	16	16	<0.1	10	10	<0.1	20	20	<0.1	189	189	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	1,443	1,350	1.1	2,130	1,995	1.5	1,374	1,308	1.9	7,685	7,171	0.9
Benign or uncertain	4,566	3,511	2.8	4,919	3,803	2.9	2,199	1,896	2.8	27,687	22,178	2.8
Metastatic	26	26	<0.1	20	20	<0.1	3	3	<0.1	272	272	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	25	23	<0.1	20	20	<0.1	4	4	<0.1	148	145	<0.1
Leukaemia or myeloma	1	1	<0.1	1	1	<0.1	0	0	0.0	9	9	<0.1
<b>Total ineligible</b>		<b>4,927</b>	<b>3.9</b>		<b>5,849</b>	<b>4.5</b>		<b>3,231</b>	<b>4.8</b>		<b>29,964</b>	<b>3.8</b>
<b>Total eligible</b>		<b>120,108</b>	<b>100.0</b>		<b>125,295</b>	<b>100.0</b>		<b>64,252</b>	<b>100.0</b>		<b>759,097</b>	<b>100.0</b>
Aged 100+	34	33	<0.1	40	39	<0.1	27	26	<0.1	245	242	<0.1
Vital status unknown	142	125	0.1	120	110	<0.1	60	40	<0.1	1,017	835	0.1
Sex not known	1	0	0.0	3	0	0.0	0	0	0.0	5	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	38	36	<0.1	17	16	<0.1	198	194	0.3	329	317	<0.1
Death certificate only	2,284	2,265	1.9	2,288	2,264	1.8	1,114	1,107	1.7	18,416	18,269	2.4
Autopsy only	74	73	<0.1	63	63	<0.1	41	41	<0.1	688	673	<0.1
Synchronous tumours	732	411	0.3	806	461	0.4	425	243	0.4	4,984	2,928	0.4
Multiple primary same site	1,412	790	0.7	1,576	907	0.7	950	578	0.9	7,373	3,828	0.5
<b>Total exclusions</b>		<b>3,733</b>	<b>3.1</b>		<b>3,860</b>	<b>3.1</b>		<b>2,229</b>	<b>3.5</b>		<b>27,092</b>	<b>3.6</b>
<b>Patients available for analyses</b>		<b>116,375</b>	<b>96.9</b>		<b>121,435</b>	<b>96.9</b>		<b>62,023</b>	<b>96.5</b>		<b>732,005</b>	<b>96.4</b>



**Table 2: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: lung cancer**

	1995-96			1997-98			1999-2000			2001-02		
Total registered	114,804	114,702	100.0	114,920	114,816	100.0	116,189	116,064	100.0	115,622	115,497	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	71	71	<0.1	47	47	<0.1	28	28	<0.1	33	33	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	20	17	<0.1	21	20	<0.1	23	21	<0.1	16	13	<0.1
Benign or uncertain	1,041	1,019	0.9	967	941	0.8	798	781	0.7	461	452	0.4
Metastatic	386	386	0.3	229	229	0.2	295	295	0.3	275	274	0.2
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	21	21	<0.1	14	14	<0.1	18	18	<0.1	17	17	<0.1
Leukaemia or myeloma	7	7	<0.1	1	1	<0.1	1	1	<0.1	5	5	<0.1
<b>Total ineligible</b>		<b>1,521</b>	<b>1.3</b>		<b>1,252</b>	<b>1.1</b>		<b>1,144</b>	<b>1.0</b>		<b>794</b>	<b>0.7</b>
<b>Total eligible</b>		<b>113,181</b>	<b>100.0</b>		<b>113,564</b>	<b>100.0</b>		<b>114,920</b>	<b>100.0</b>		<b>114,703</b>	<b>100.0</b>
Aged 100+	6	6	<0.1	8	8	<0.1	11	11	<0.1	12	11	<0.1
Vital status unknown	152	82	<0.1	144	97	<0.1	205	178	0.2	138	106	<0.1
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	18	14	<0.1	37	33	<0.1	14	13	<0.1	7	6	<0.1
Death certificate only	7,626	7,585	6.7	7,108	7,088	6.2	6,080	6,065	5.3	4,671	4,659	4.1
Autopsy only	391	386	0.3	328	320	0.3	248	246	0.2	243	240	0.2
Synchronous tumours	259	238	0.2	260	236	0.2	491	445	0.4	263	206	0.2
Multiple primary same site	63	12	<0.1	100	41	<0.1	162	88	<0.1	196	116	0.1
<b>Total exclusions</b>		<b>8,323</b>	<b>7.4</b>		<b>7,823</b>	<b>6.9</b>		<b>7,046</b>	<b>6.1</b>		<b>5,344</b>	<b>4.7</b>
<b>Patients available for analyses</b>		<b>104,858</b>	<b>92.6</b>		<b>105,741</b>	<b>93.1</b>		<b>107,874</b>	<b>93.9</b>		<b>109,359</b>	<b>95.3</b>

  

	2003-04			2005-06			2007			1995-2007		
Total registered	118,510	118,367	100.0	123,098	122,925	100.0	62,327	62,236	100.0	765,470	764,607	100.0
Ineligible	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Incomplete data	9	9	<0.1	14	14	<0.1	7	7	<0.1	209	209	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	20	20	<0.1	16	16	<0.1	7	6	<0.1	123	113	<0.1
Benign or uncertain	366	345	0.3	289	269	0.2	153	147	0.2	4,075	3,954	0.5
Metastatic	104	104	<0.1	96	93	<0.1	28	28	<0.1	1,413	1,409	0.2
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	18	17	<0.1	19	18	<0.1	9	8	<0.1	116	113	<0.1
Leukaemia or myeloma	1	1	<0.1	1	1	<0.1	1	1	<0.1	17	17	<0.1
<b>Total ineligible</b>		<b>496</b>	<b>0.4</b>		<b>411</b>	<b>0.3</b>		<b>197</b>	<b>0.3</b>		<b>5,815</b>	<b>0.8</b>
<b>Total eligible</b>		<b>117,871</b>	<b>100.0</b>		<b>122,514</b>	<b>100.0</b>		<b>62,039</b>	<b>100.0</b>		<b>758,792</b>	<b>100.0</b>
Aged 100+	14	14	<0.1	25	25	<0.1	7	5	<0.1	83	80	<0.1
Vital status unknown	102	94	<0.1	86	72	<0.1	23	16	<0.1	850	645	<0.1
Sex not known	0	0	0.0	1	0	0.0	0	0	0.0	1	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	15	14	<0.1	13	8	<0.1	31	28	<0.1	135	116	<0.1
Death certificate only	5,280	5,264	4.5	5,091	5,063	4.1	2,844	2,837	4.6	38,700	38,561	5.1
Autopsy only	146	145	0.1	167	166	0.1	113	113	0.2	1,636	1,616	0.2
Synchronous tumours	234	190	0.2	281	221	0.2	147	108	0.2	1,935	1,644	0.2
Multiple primary same site	262	164	0.1	343	225	0.2	218	154	0.2	1,344	800	0.1
<b>Total exclusions</b>		<b>5,885</b>	<b>5.0</b>		<b>5,780</b>	<b>4.7</b>		<b>3,261</b>	<b>5.3</b>		<b>43,462</b>	<b>5.7</b>
<b>Patients available for analyses</b>		<b>111,986</b>	<b>95.0</b>		<b>116,734</b>	<b>95.3</b>		<b>58,778</b>	<b>94.7</b>		<b>715,330</b>	<b>94.3</b>

**Table 3: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions combined: breast cancer (women)**

	1995-96			1997-98			1999-2000			2001-02		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Total registered	122,919	122,393	100.0	132,491	131,604	100.0	139,188	138,172	100.0	143,751	142,614	100.0
<b>Ineligible</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>
Incomplete data	105	105	<0.1	69	68	<0.1	37	36	<0.1	14	14	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	5,218	5,027	4.1	6,547	6,307	4.8	7,604	7,349	5.3	8,458	8,188	5.7
Benign or uncertain	358	342	0.3	405	389	0.3	297	280	0.2	313	279	0.2
Metastatic	21	21	<0.1	21	20	<0.1	30	30	<0.1	21	21	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	15	15	<0.1	17	17	<0.1	18	18	<0.1	13	13	<0.1
Leukaemia or myeloma	1	1	<0.1	0	0	0.0	0	0	0.0	0	0	0.0
<b>Total ineligible</b>		<b>5,511</b>	<b>4.5</b>		<b>6,801</b>	<b>5.2</b>		<b>7,713</b>	<b>5.6</b>		<b>8,515</b>	<b>6.0</b>
<b>Total eligible</b>		<b>116,882</b>	<b>100.0</b>		<b>124,803</b>	<b>100.0</b>		<b>130,459</b>	<b>100.0</b>		<b>134,099</b>	<b>100.0</b>
Aged 100+	65	65	<0.1	56	56	<0.1	82	82	<0.1	77	76	<0.1
Vital status unknown	285	190	0.2	262	201	0.2	303	266	0.2	300	283	0.2
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	4	4	<0.1	9	7	<0.1	6	6	<0.1	35	34	<0.1
Death certificate only	2,673	2,627	2.2	2,863	2,817	2.3	2,299	2,256	1.7	1,716	1,684	1.3
Autopsy only	20	20	<0.1	20	19	<0.1	15	15	<0.1	9	9	<0.1
Synchronous tumours	673	539	0.5	920	577	0.5	1,489	1,057	0.8	1,140	697	0.5
Multiple primary same site	324	55	<0.1	878	414	0.3	1,358	834	0.6	1,761	1,153	0.9
<b>Total exclusions</b>		<b>3,500</b>	<b>3.0</b>		<b>4,091</b>	<b>3.3</b>		<b>4,516</b>	<b>3.5</b>		<b>3,936</b>	<b>2.9</b>
<b>Patients available for analyses</b>		<b>113,382</b>	<b>97.0</b>		<b>120,712</b>	<b>96.7</b>		<b>125,943</b>	<b>96.5</b>		<b>130,163</b>	<b>97.1</b>

	2003-04			2005-06			2007			1995-2007		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
Total registered	150,970	149,318	100.0	156,212	154,153	100.0	78,762	77,925	100.0	924,293	916,179	100.0
<b>Ineligible</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>	<b>Records</b>	<b>Patients</b>	<b>%</b>
Incomplete data	17	17	<0.1	14	14	<0.1	5	5	<0.1	261	259	<0.1
Not resident in England or Wales	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
In situ neoplasm	9,866	9,337	6.3	11,532	10,768	7.0	5,988	5,729	7.4	55,213	52,705	5.8
Benign or uncertain	301	261	0.2	349	311	0.2	202	187	0.2	2,225	2,049	0.2
Metastatic	10	10	<0.1	9	9	<0.1	2	1	<0.1	114	112	<0.1
Otherwise ineligible	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Lymphoma	12	11	<0.1	6	6	<0.1	3	2	<0.1	84	82	<0.1
Leukaemia or myeloma	0	0	0.0	0	0	0.0	0	0	0.0	1	1	<0.1
<b>Total ineligible</b>		<b>9,636</b>	<b>6.5</b>		<b>11,108</b>	<b>7.2</b>		<b>5,924</b>	<b>7.6</b>		<b>55,208</b>	<b>6.0</b>
<b>Total eligible</b>		<b>139,682</b>	<b>100.0</b>		<b>143,045</b>	<b>100.0</b>		<b>72,001</b>	<b>100.0</b>		<b>860,971</b>	<b>100.0</b>
Aged 100+	77	77	<0.1	92	91	<0.1	39	39	<0.1	488	486	<0.1
Vital status unknown	265	247	0.2	313	303	0.2	81	76	0.1	1,809	1,566	0.2
Sex not known	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Sex-site error	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Invalid dates	62	58	<0.1	20	18	<0.1	23	22	<0.1	159	149	<0.1
Death certificate only	1,523	1,485	1.1	1,188	1,151	0.8	591	572	0.8	12,853	12,592	1.5
Autopsy only	10	10	<0.1	11	11	<0.1	6	6	<0.1	91	90	<0.1
Synchronous tumours	1,493	932	0.7	1,544	860	0.6	724	412	0.6	7,983	5,074	0.6
Multiple primary same site	2,488	1,660	1.2	3,201	2,278	1.6	1,682	1,270	1.8	11,692	7,664	0.9
<b>Total exclusions</b>		<b>4,469</b>	<b>3.2</b>		<b>4,712</b>	<b>3.3</b>		<b>2,397</b>	<b>3.3</b>		<b>27,621</b>	<b>3.2</b>
<b>Patients available for analyses</b>		<b>135,213</b>	<b>96.8</b>		<b>138,333</b>	<b>96.7</b>		<b>69,604</b>	<b>96.7</b>		<b>833,350</b>	<b>96.8</b>

**Table 4: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis (1995-2007), all 12 jurisdictions (except Swedish regions) combined: ovarian cancer**

	1995-96			1997-98			1999-2000			2001-02		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
<b>Total registered</b>	<b>20,194</b>	<b>20,134</b>	<b>100.0</b>	<b>21,193</b>	<b>21,150</b>	<b>100.0</b>	<b>21,172</b>	<b>21,124</b>	<b>100.0</b>	<b>21,778</b>	<b>21,713</b>	<b>100.0</b>
<b>Ineligible</b>												
<b>Incomplete data</b>	30	30	0.1	8	8	<0.1	5	5	<0.1	25	25	0.1
<b>Not resident in England or Wales</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>In situ neoplasm</b>	197	195	1.0	80	79	0.4	29	28	0.1	35	35	0.2
<b>Benign or uncertain</b>	1,586	1,562	7.8	1,729	1,713	8.1	1,658	1,633	7.7	1,626	1,569	7.2
<b>Metastatic</b>	110	110	0.5	48	48	0.2	91	91	0.4	60	60	0.3
<b>Otherwise ineligible</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Lymphoma</b>	1	1	<0.1	2	2	<0.1	0	0	0.0	0	0	0.0
<b>Leukaemia or myeloma</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Total ineligible</b>		<b>1,898</b>	<b>9.4</b>		<b>1,850</b>	<b>8.7</b>		<b>1,757</b>	<b>8.3</b>		<b>1,689</b>	<b>7.8</b>
<b>Total eligible</b>		<b>18,236</b>	<b>100.0</b>		<b>19,300</b>	<b>100.0</b>		<b>19,367</b>	<b>100.0</b>		<b>20,024</b>	<b>100.0</b>
<b>Aged 100+</b>	4	4	<0.1	0	0	0.0	7	7	<0.1	5	5	<0.1
<b>Vital status unknown</b>	45	18	<0.1	29	21	0.1	33	28	0.1	32	28	0.1
<b>Sex not known</b>	0	0	0.0	1	1	<0.1	0	0	0.0	0	0	0.0
<b>Sex-site error</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Invalid dates</b>	3	2	<0.1	3	3	<0.1	0	0	0.0	3	3	<0.1
<b>Death certificate only</b>	790	784	4.3	797	790	4.1	770	764	3.9	592	588	2.9
<b>Autopsy only</b>	29	29	0.2	16	16	<0.1	13	13	<0.1	12	12	<0.1
<b>Synchronous tumours</b>	45	23	0.1	40	25	0.1	59	45	0.2	48	29	0.1
<b>Multiple primary same site</b>	34	9	<0.1	34	16	<0.1	28	12	<0.1	35	15	<0.1
<b>Total exclusions</b>		<b>869</b>	<b>4.8</b>		<b>872</b>	<b>4.5</b>		<b>869</b>	<b>4.5</b>		<b>680</b>	<b>3.4</b>
<b>Patients available for analyses</b>		<b>17,367</b>	<b>95.2</b>		<b>18,428</b>	<b>95.5</b>		<b>18,498</b>	<b>95.5</b>		<b>19,344</b>	<b>96.6</b>
	2003-04			2005-06			2007			1995-2007		
	Records	Patients	%	Records	Patients	%	Records	Patients	%	Records	Patients	%
<b>Total registered</b>	<b>21,245</b>	<b>21,203</b>	<b>100.0</b>	<b>21,295</b>	<b>21,250</b>	<b>100.0</b>	<b>10,648</b>	<b>10,625</b>	<b>100.0</b>	<b>137,525</b>	<b>137,199</b>	<b>100.0</b>
<b>Ineligible</b>												
<b>Incomplete data</b>	9	9	<0.1	24	24	0.1	3	3	<0.1	104	104	<0.1
<b>Not resident in England or Wales</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>In situ neoplasm</b>	28	25	0.1	29	26	0.1	46	46	0.4	444	434	0.3
<b>Benign or uncertain</b>	1,529	1,501	7.1	1,593	1,577	7.4	868	854	8.0	10,589	10,409	7.6
<b>Metastatic</b>	29	29	0.1	19	19	<0.1	6	6	<0.1	363	363	0.3
<b>Otherwise ineligible</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Lymphoma</b>	4	4	<0.1	1	1	<0.1	0	0	0.0	8	8	<0.1
<b>Leukaemia or myeloma</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Total ineligible</b>		<b>1,568</b>	<b>7.4</b>		<b>1,647</b>	<b>7.8</b>		<b>909</b>	<b>8.6</b>		<b>11,318</b>	<b>8.2</b>
<b>Total eligible</b>		<b>19,635</b>	<b>100.0</b>		<b>19,603</b>	<b>100.0</b>		<b>9,716</b>	<b>100.0</b>		<b>125,881</b>	<b>100.0</b>
<b>Aged 100+</b>	8	8	<0.1	5	5	<0.1	5	5	<0.1	34	34	<0.1
<b>Vital status unknown</b>	26	26	0.1	54	32	0.2	11	9	<0.1	230	162	0.1
<b>Sex not known</b>	0	0	0.0	0	0	0.0	0	0	0.0	1	1	<0.1
<b>Sex-site error</b>	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
<b>Invalid dates</b>	3	3	<0.1	2	2	<0.1	9	8	<0.1	23	21	<0.1
<b>Death certificate only</b>	523	519	2.6	474	470	2.4	268	266	2.7	4,214	4,181	3.3
<b>Autopsy only</b>	11	11	<0.1	18	18	<0.1	5	5	<0.1	104	104	<0.1
<b>Synchronous tumours</b>	53	37	0.2	50	34	0.2	20	14	0.1	315	207	0.2
<b>Multiple primary same site</b>	41	28	0.1	36	21	0.1	19	11	0.1	227	112	<0.1
<b>Total exclusions</b>		<b>632</b>	<b>3.2</b>		<b>582</b>	<b>3.0</b>		<b>318</b>	<b>3.3</b>		<b>4,822</b>	<b>3.8</b>
<b>Patients available for analyses</b>		<b>19,003</b>	<b>96.8</b>		<b>19,021</b>	<b>97.0</b>		<b>9,398</b>	<b>96.7</b>		<b>121,059</b>	<b>96.2</b>

**Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer**

		1995-99						2000-02						2005-07 <sup>a</sup>					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	<b>15-44</b>	597	517	611	532	1,208	1,049	379	348	385	345	764	693	662	484	716	530	1,378	1,014
	<b>45-54</b>	1,720	1,469	1,349	1,155	3,069	2,624	1,118	980	904	793	2,022	1,773	1,774	1,306	1,547	1,131	3,321	2,437
	<b>55-64</b>	3,982	3,275	2,568	2,151	6,550	5,426	2,529	2,188	1,728	1,500	4,257	3,688	4,551	3,345	3,011	2,160	7,562	5,505
	<b>65-74</b>	6,346	4,932	4,415	3,560	10,761	8,492	3,953	3,249	2,709	2,191	6,662	5,440	6,592	4,624	4,452	3,112	11,044	7,736
	<b>75-99</b>	5,202	3,460	5,831	3,875	11,033	7,335	3,922	2,671	4,038	2,739	7,960	5,410	6,896	4,340	7,000	4,488	13,896	8,828
	<b>Total</b>	17,847	13,653	14,774	11,273	32,621	24,926	11,901	9,436	9,764	7,568	21,665	17,004	20,475	14,099	16,726	11,421	37,201	25,520
New South Wales	<b>15-44</b>	322	280	330	290	652	570	217	202	188	170	405	372	371	264	378	272	749	536
	<b>45-54</b>	1,022	868	779	653	1,801	1,521	603	528	516	457	1,119	985	1,027	751	850	626	1,877	1,377
	<b>55-64</b>	2,298	1,898	1,517	1,265	3,815	3,163	1,501	1,314	1,045	919	2,546	2,233	2,633	1,913	1,778	1,257	4,411	3,170
	<b>65-74</b>	3,561	2,799	2,416	1,960	5,977	4,759	2,209	1,826	1,520	1,232	3,729	3,058	3,773	2,636	2,536	1,776	6,309	4,412
	<b>75-99</b>	2,906	1,940	3,207	2,141	6,113	4,081	2,099	1,453	2,177	1,465	4,276	2,918	3,804	2,368	3,961	2,561	7,765	4,929
	<b>Total</b>	10,109	7,785	8,249	6,309	18,358	14,094	6,629	5,323	5,446	4,243	12,075	9,566	11,608	7,932	9,503	6,492	21,111	14,424
Victoria	<b>15-44</b>	275	237	281	242	556	479	162	146	197	175	359	321	291	220	338	258	629	478
	<b>45-54</b>	698	601	570	502	1,268	1,103	515	452	388	336	903	788	747	555	697	505	1,444	1,060
	<b>55-64</b>	1,684	1,377	1,051	886	2,735	2,263	1,028	874	683	581	1,711	1,455	1,918	1,432	1,233	903	3,151	2,335
	<b>65-74</b>	2,785	2,133	1,999	1,600	4,784	3,733	1,744	1,423	1,189	959	2,933	2,382	2,819	1,988	1,916	1,336	4,735	3,324
	<b>75-99</b>	2,296	1,520	2,624	1,734	4,920	3,254	1,823	1,218	1,861	1,274	3,684	2,492	3,092	1,972	3,039	1,927	6,131	3,899
	<b>Total</b>	7,738	5,868	6,525	4,964	14,263	10,832	5,272	4,113	4,318	3,325	9,590	7,438	8,867	6,167	7,223	4,929	16,090	11,096
Canadian registries	<b>15-44</b>	920	768	871	729	1,791	1,497	622	544	598	528	1,220	1,072	1,053	786	1,009	737	2,062	1,523
	<b>45-54</b>	2,368	1,993	1,942	1,637	4,310	3,630	1,745	1,506	1,422	1,249	3,167	2,755	3,289	2,358	2,536	1,855	5,825	4,213
	<b>55-64</b>	5,336	4,355	3,553	2,957	8,889	7,312	3,697	3,128	2,497	2,145	6,194	5,273	6,926	4,913	4,490	3,221	11,416	8,134
	<b>65-74</b>	8,912	6,912	6,323	4,978	15,235	11,890	5,832	4,656	3,971	3,253	9,803	7,909	9,504	6,726	6,512	4,601	16,016	11,327
	<b>75-99</b>	8,144	5,417	9,463	6,256	17,607	11,673	5,801	4,001	6,564	4,399	12,365	8,400	9,878	6,149	10,887	6,850	20,765	12,999
	<b>Total</b>	25,680	19,445	22,152	16,557	47,832	36,002	17,697	13,835	15,052	11,574	32,749	25,409	30,650	20,932	25,434	17,264	56,084	38,196
Alberta	<b>15-44</b>	120	99	113	90	233	189	93	74	78	72	171	146	168	126	132	89	300	215
	<b>45-54</b>	304	251	224	183	528	434	227	189	197	166	424	355	525	369	378	288	903	657
	<b>55-64</b>	689	549	403	324	1,092	873	480	408	333	281	813	689	880	624	561	392	1,441	1,016
	<b>65-74</b>	1,052	811	641	507	1,693	1,318	751	594	454	366	1,205	960	1,162	802	817	542	1,979	1,344
	<b>75-99</b>	1,036	653	1,079	701	2,115	1,354	694	455	720	468	1,414	923	1,289	797	1,280	803	2,569	1,600
	<b>Total</b>	3,201	2,363	2,460	1,805	5,661	4,168	2,245	1,720	1,782	1,353	4,027	3,073	4,024	2,718	3,168	2,114	7,192	4,832
British Columbia	<b>15-44</b>	163	137	161	140	324	277	104	94	131	116	235	210	178	135	179	140	357	275
	<b>45-54</b>	444	372	359	299	803	671	336	291	275	237	611	528	586	424	521	386	1,107	810
	<b>55-64</b>	1,015	837	687	582	1,702	1,419	693	590	491	421	1,184	1,011	1,358	956	894	656	2,252	1,612
	<b>65-74</b>	1,824	1,453	1,235	1,000	3,059	2,453	1,156	918	779	647	1,935	1,565	1,918	1,403	1,306	947	3,293	2,350
	<b>75-99</b>	1,874	1,273	1,974	1,355	3,848	2,628	1,349	957	1,445	998	2,794	1,955	2,241	1,437	2,272	1,424	4,513	2,861
	<b>Total</b>	5,320	4,072	4,416	3,376	9,736	7,448	3,638	2,850	3,121	2,419	6,759	5,269	6,350	4,355	5,172	3,553	11,522	7,908
Manitoba	<b>15-44</b>	71	63	44	36	115	99	44	35	36	30	80	65	61	46	69	50	130	96
	<b>45-54</b>	156	127	122	103	278	230	99	90	78	69	177	159	202	139	144	99	346	238
	<b>55-64</b>	333	283	221	191	554	474	227	175	143	118	370	293	434	295	257	178	691	473
	<b>65-74</b>	571	443	414	322	985	765	321	262	244	202	565	464	478	332	348	238	826	570
	<b>75-99</b>	602	401	720	474	1,322	875	433	293	470	317	903	610	636	397	749	466	1,385	863
	<b>Total</b>	1,733	1,317	1,521	1,126	3,254	2,443	1,124	855	971	736	2,095	1,591	1,811	1,209	1,567	1,031	3,378	2,240

**Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer**

		1995-99						2000-02						2005-07 <sup>a</sup>					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors	All	1-year survivors
<b>Ontario</b>	<b>15-44</b>	566	469	553	463	1,119	932	381	341	353	310	734	651	646	479	629	458	1,275	937
	<b>45-54</b>	1,464	1,243	1,237	1,052	2,701	2,295	1,083	936	872	777	1,955	1,713	1,976	1,426	1,493	1,082	3,469	2,508
	<b>55-64</b>	3,299	2,686	2,242	1,860	5,541	4,546	2,297	1,955	1,530	1,325	3,827	3,280	4,254	3,038	2,778	1,995	7,032	5,033
	<b>65-74</b>	5,465	4,205	4,033	3,149	9,498	7,354	3,604	2,882	2,494	2,038	6,098	4,920	5,877	4,189	4,041	2,874	9,918	7,063
	<b>75-99</b>	4,632	3,090	5,690	3,726	10,322	6,816	3,325	2,296	3,929	2,616	7,254	4,912	5,712	3,518	6,586	4,157	12,298	7,675
	<b>Total</b>	15,426	11,693	13,755	10,250	29,181	21,943	10,690	8,410	9,178	7,066	19,868	15,476	18,465	12,650	15,527	10,566	33,992	23,216
<b>Denmark</b>	<b>15-44</b>	185	156	201	163	386	319	116	93	106	89	222	182	206	145	200	137	406	282
	<b>45-54</b>	693	520	615	497	1,308	1,017	448	369	372	321	820	690	747	505	649	489	1,396	994
	<b>55-64</b>	1,634	1,235	1,309	1,011	2,943	2,246	1,136	914	876	727	2,012	1,641	2,161	1,502	1,671	1,161	3,832	2,663
	<b>65-74</b>	2,571	1,740	2,347	1,679	4,918	3,419	1,725	1,225	1,372	967	3,097	2,192	3,127	2,087	2,319	1,566	5,446	3,653
	<b>75-99</b>	3,016	1,662	3,822	2,188	6,838	3,850	1,941	1,073	2,344	1,334	4,285	2,407	3,147	1,725	3,791	2,080	6,938	3,805
	<b>Total</b>	8,099	5,313	8,294	5,538	16,393	10,851	5,366	3,674	5,070	3,438	10,436	7,112	9,388	5,964	8,630	5,433	18,018	11,397
<b>Norway</b>	<b>15-44</b>	158	125	211	182	369	307	115	97	123	108	238	205	216	155	242	188	458	343
	<b>45-54</b>	540	440	564	480	1,104	920	333	265	355	305	688	570	598	448	563	416	1,161	864
	<b>55-64</b>	1,201	970	1,064	906	2,265	1,876	860	715	748	640	1,608	1,355	1,596	1,141	1,337	957	2,933	2,098
	<b>65-74</b>	2,382	1,828	2,017	1,593	4,399	3,421	1,413	1,068	1,164	938	2,577	2,006	2,265	1,545	1,965	1,390	4,230	2,935
	<b>75-99</b>	2,840	1,808	3,726	2,401	6,566	4,209	1,988	1,215	2,419	1,567	4,407	2,782	3,150	1,982	3,828	2,344	6,978	4,326
	<b>Total</b>	7,121	5,171	7,582	5,562	14,703	10,733	4,709	3,360	4,809	3,558	9,518	6,918	7,825	5,271	7,935	5,295	15,760	10,566
<b>Swedish regions</b>	<b>15-44</b>	82	70	72	63	154	133	74	63	66	61	140	124	129	94	107	79	236	173
	<b>45-54</b>	276	236	238	210	514	446	217	186	168	143	385	329	311	234	310	230	621	464
	<b>55-64</b>	623	514	494	402	1,117	916	567	495	429	363	996	858	1,024	741	849	621	1,873	1,362
	<b>65-74</b>	1,223	982	1,006	822	2,229	1,804	890	727	751	607	1,641	1,334	1,571	1,124	1,246	864	2,817	1,988
	<b>75-99</b>	1,595	1,102	1,773	1,265	3,368	2,367	1,250	871	1,374	987	2,624	1,858	2,111	1,384	2,292	1,506	4,403	2,890
	<b>Total</b>	3,799	2,904	3,583	2,762	7,382	5,666	2,998	2,342	2,788	2,161	5,786	4,503	5,146	3,577	4,804	3,300	9,950	6,877
<b>UK-England</b>	<b>15-44</b>	1,580	1,265	1,462	1,184	3,042	2,449	1,028	842	968	833	1,996	1,675	1,891	1,317	1,809	1,243	3,700	2,560
	<b>45-54</b>	5,274	4,165	4,100	3,310	9,374	7,475	3,077	2,449	2,485	2,074	5,562	4,523	4,959	3,522	3,919	2,761	8,878	6,283
	<b>55-64</b>	13,577	10,273	8,667	6,737	22,244	17,010	8,475	6,695	5,358	4,321	13,833	11,016	14,627	10,085	9,512	6,410	24,139	16,495
	<b>65-74</b>	24,147	16,619	17,343	12,099	41,490	28,718	14,424	10,411	9,741	7,056	24,165	17,467	23,409	15,191	15,335	10,065	38,744	25,256
	<b>75-99</b>	24,570	13,204	29,556	15,138	54,126	28,342	16,929	9,382	18,353	9,822	35,282	19,204	27,105	14,836	27,481	14,610	54,586	29,446
	<b>Total</b>	69,148	45,526	61,128	38,468	130,276	83,994	43,933	29,779	36,905	24,106	80,838	53,885	71,991	44,951	58,056	35,089	130,047	80,040
<b>UK-Northern Ireland</b>	<b>15-44</b>	73	62	69	56	142	118	34	30	39	35	73	65	81	43	59	33	140	76
	<b>45-54</b>	197	158	158	135	355	293	118	96	99	86	217	182	204	144	177	122	381	266
	<b>55-64</b>	437	356	382	306	819	662	323	261	233	197	556	458	557	378	345	225	902	603
	<b>65-74</b>	791	559	599	447	1,390	1,006	451	335	327	252	778	587	867	555	577	375	1,444	930
	<b>75-99</b>	759	425	965	549	1,724	974	445	251	521	321	966	572	828	448	845	440	1,673	888
	<b>Total</b>	2,257	1,560	2,173	1,493	4,430	3,053	1,371	973	1,219	891	2,590	1,864	2,537	1,568	2,003	1,195	4,540	2,763
<b>UK-Wales</b>	<b>15-44</b>	122	89	108	92	230	181	68	58	60	53	128	111	122	85	112	81	234	166
	<b>45-54</b>	386	310	276	218	662	528	230	186	170	139	400	325	330	223	284	190	614	413
	<b>55-64</b>	1,006	750	603	455	1,609	1,205	598	457	356	279	954	736	1,075	701	690	457	1,765	1,158
	<b>65-74</b>	1,822	1,190	1,191	825	3,013	2,015	1,063	749	642	474	1,705	1,223	1,697	1,093	1,033	645	2,730	1,738
	<b>75-99</b>	1,759	911	2,109	1,028	3,868	1,939	1,168	659	1,216	634	2,384	1,293	1,965	1,086	1,748	905	3,713	1,991
	<b>Total</b>	5,095	3,250	4,287	2,618	9,382	5,868	3,127	2,109	2,444	1,579	5,571	3,688	5,189	3,188	3,867	2,278	9,056	5,466

<sup>a</sup> No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

**Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer**

		1995-99						2000-02						2005-07 <sup>a</sup>					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-year survivors
<b>Australian registries</b>	<b>15-44</b>	232	119	218	127	450	246	136	68	141	84	277	152	213	115	222	126	435	241
	<b>45-54</b>	1,080	425	714	345	1,794	770	601	269	461	251	1,062	520	872	351	787	372	1,659	723
	<b>55-64</b>	3,076	1,242	1,408	649	4,484	1,891	1,854	756	1,033	514	2,887	1,270	2,610	1,144	1,780	867	4,390	2,011
	<b>65-74</b>	6,292	2,246	2,642	1,032	8,934	3,278	3,377	1,261	1,554	642	4,931	1,903	4,301	1,706	2,349	971	6,650	2,677
	<b>75-99</b>	4,777	1,189	2,388	636	7,165	1,825	3,271	947	1,878	531	5,149	1,478	4,998	1,425	2,969	881	7,967	2,306
	<b>Total</b>	15,457	5,221	7,370	2,789	22,827	8,010	9,239	3,301	5,067	2,022	14,306	5,323	12,994	4,741	8,107	3,217	21,101	7,958
<b>New South Wales</b>	<b>15-44</b>	140	68	138	79	278	147	78	43	88	54	166	97	114	58	127	68	241	126
	<b>45-54</b>	608	238	427	207	1,035	445	388	178	274	145	662	323	495	198	457	224	952	422
	<b>55-64</b>	1,790	711	805	369	2,595	1,080	1,067	427	584	294	1,651	721	1,522	675	1,076	545	2,598	1,220
	<b>65-74</b>	3,633	1,274	1,524	612	5,157	1,886	1,973	746	872	354	2,845	1,100	2,484	997	1,352	551	3,836	1,548
	<b>75-99</b>	2,740	688	1,267	350	4,007	1,038	1,878	526	1,026	307	2,904	833	2,809	763	1,677	487	4,486	1,250
	<b>Total</b>	8,911	2,979	4,161	1,617	13,072	4,596	5,384	1,920	2,844	1,154	8,228	3,074	7,424	2,691	4,689	1,875	12,113	4,566
<b>Victoria</b>	<b>15-44</b>	92	51	80	48	172	99	58	25	53	30	111	55	99	57	95	58	194	115
	<b>45-54</b>	472	187	287	138	759	325	213	91	187	106	400	197	377	153	330	148	707	301
	<b>55-64</b>	1,286	531	603	280	1,889	811	787	329	449	220	1,236	549	1,088	469	704	322	1,792	791
	<b>65-74</b>	2,659	972	1,118	420	3,777	1,392	1,404	515	682	288	2,086	803	1,817	709	997	420	2,814	1,129
	<b>75-99</b>	2,037	501	1,121	286	3,158	787	1,393	421	852	224	2,245	645	2,189	662	1,292	394	3,481	1,056
	<b>Total</b>	6,546	2,242	3,209	1,172	9,755	3,414	3,855	1,381	2,223	868	6,078	2,249	5,570	2,050	3,418	1,342	8,988	3,392
<b>Canadian registries</b>	<b>15-44</b>	629	273	745	366	1,374	639	369	178	476	254	845	432	398	205	544	329	942	534
	<b>45-54</b>	2,516	983	2,407	1,190	4,923	2,173	1,615	625	1,557	783	3,172	1,408	2,023	820	2,479	1,172	4,502	1,992
	<b>55-64</b>	6,872	2,691	4,958	2,318	11,830	5,009	4,008	1,523	3,268	1,601	7,276	3,124	5,671	2,257	5,269	2,399	10,940	4,656
	<b>65-74</b>	12,089	4,308	7,690	3,184	19,779	7,492	6,971	2,576	4,840	2,047	11,811	4,623	9,005	3,469	7,459	3,224	16,464	6,693
	<b>75-99</b>	9,081	2,477	6,329	1,991	15,410	4,468	6,061	1,692	4,991	1,547	11,052	3,239	8,982	2,588	7,848	2,700	16,830	5,288
	<b>Total</b>	31,187	10,732	22,129	9,049	53,316	19,781	19,024	6,594	15,132	6,232	34,156	12,826	26,079	9,339	23,599	9,824	49,678	19,163
<b>Alberta</b>	<b>15-44</b>	73	21	86	43	159	64	41	20	57	20	98	38	43	20	80	53	123	73
	<b>45-54</b>	306	97	307	150	613	247	205	57	183	83	388	140	276	108	335	136	611	244
	<b>55-64</b>	829	305	656	287	1,485	592	460	163	434	181	894	344	720	272	784	360	1,504	632
	<b>65-74</b>	1,444	463	880	320	2,324	783	840	280	615	245	1,455	525	1,152	415	954	407	2,106	822
	<b>75-99</b>	1,189	283	743	233	1,932	516	795	199	634	190	1,429	389	1,198	333	994	343	2,192	676
	<b>Total</b>	3,841	1,169	2,672	1,033	6,513	2,202	2,341	717	1,923	719	4,264	1,436	3,389	1,148	3,147	1,299	6,536	2,447
<b>British Columbia</b>	<b>15-44</b>	129	51	167	83	296	134	62	30	85	43	147	75	55	28	86	49	141	77
	<b>45-54</b>	487	175	530	241	1,017	416	285	97	353	171	638	268	380	149	506	248	886	397
	<b>55-64</b>	1,343	508	968	427	2,311	935	712	248	652	289	1,364	537	1,110	385	1,081	486	2,191	871
	<b>65-74</b>	2,382	841	1,609	634	3,991	1,475	1,354	491	961	387	2,315	878	1,779	658	1,615	680	3,394	1,338
	<b>75-99</b>	2,002	493	1,541	433	3,543	926	1,328	334	1,185	364	2,513	698	1,950	544	1,759	579	3,709	1,123
	<b>Total</b>	6,343	2,068	4,815	1,818	11,158	3,886	3,741	1,202	3,236	1,254	6,977	2,456	5,274	1,764	5,047	2,042	10,321	3,806
<b>Manitoba</b>	<b>15-44</b>	20	13	29	14	49	23	15	5	26	16	41	21	17	12	27	18	44	30
	<b>45-54</b>	129	48	140	65	269	113	80	27	87	51	167	79	133	47	145	74	278	121
	<b>55-64</b>	397	148	300	158	697	306	248	94	235	119	483	213	316	127	338	151	654	278
	<b>65-74</b>	664	245	457	199	1,121	444	377	149	289	144	666	293	580	203	454	213	1,034	416
	<b>75-99</b>	585	202	393	156	978	358	399	141	357	140	756	281	602	191	574	240	1,176	431
	<b>Total</b>	1,795	656	1,319	588	3,114	1,244	1,119	417	994	470	2,113	887	1,648	580	1,538	696	3,186	1,276

**Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer**

		1995-99						2000-02						2005-07 <sup>a</sup>					
		Men		Women		Persons		Men		Women		Persons		Men		Women		Persons	
		All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-yr survivors	All	1-year survivors
<b>Ontario</b>	<b>15-44</b>	407	188	463	230	870	418	251	123	308	175	559	298	283	145	351	209	634	354
	<b>45-54</b>	1,594	663	1,430	734	3,024	1,397	1,045	443	934	478	1,979	921	1,234	516	1,493	714	2,727	1,230
	<b>55-64</b>	4,303	1,730	3,034	1,446	7,337	3,176	2,588	1,018	1,947	1,012	4,535	2,030	3,525	1,473	3,066	1,402	6,591	2,875
	<b>65-74</b>	7,599	2,759	4,744	2,031	12,343	4,790	4,400	1,656	2,975	1,271	7,375	2,927	5,494	2,193	4,436	1,924	9,930	4,117
	<b>75-99</b>	5,305	1,499	3,652	1,169	8,957	2,668	3,539	1,018	2,815	853	6,354	1,871	5,232	1,520	4,521	1,538	9,753	3,058
	<b>Total</b>	19,208	6,839	13,323	5,610	32,531	12,449	11,823	4,258	8,979	3,789	20,802	8,047	15,768	5,847	13,867	5,787	29,635	11,634
<b>Denmark</b>	<b>15-44</b>	177	61	186	74	363	135	113	48	100	55	213	103	111	51	145	58	256	109
	<b>45-54</b>	852	279	840	321	1,692	600	517	192	498	205	1,015	397	601	250	760	314	1,361	564
	<b>55-64</b>	2,262	656	1,773	613	4,035	1,269	1,414	478	1,150	468	2,564	946	2,123	740	1,908	784	4,031	1,524
	<b>65-74</b>	3,698	883	2,461	638	6,159	1,521	2,374	652	1,695	539	4,069	1,191	2,901	964	2,456	888	5,357	1,852
	<b>75-99</b>	2,645	412	1,590	243	4,235	655	1,811	333	1,300	254	3,111	587	2,438	505	1,976	441	4,414	946
	<b>Total</b>	9,634	2,291	6,850	1,889	16,484	4,180	6,229	1,703	4,743	1,521	10,972	3,224	8,174	2,510	7,245	2,485	15,419	4,995
<b>Norway</b>	<b>15-44</b>	120	67	100	45	220	112	56	62	118	62	118	70	34	82	45	152	79	
	<b>45-54</b>	602	248	437	173	1,039	421	338	118	283	137	621	255	392	165	368	173	760	338
	<b>55-64</b>	1,185	399	692	277	1,877	676	803	266	558	220	1,361	486	1,314	491	1,013	423	2,327	914
	<b>65-74</b>	2,366	661	1,143	371	3,509	1,032	1,314	395	769	262	2,083	657	1,693	637	1,177	460	2,870	1,097
	<b>75-99</b>	1,912	420	856	178	2,768	598	1,390	278	677	152	2,067	430	1,868	470	1,169	308	3,037	778
	<b>Total</b>	6,185	1,795	3,228	1,044	9,413	2,839	3,901	1,081	2,349	801	6,250	1,882	5,337	1,797	3,809	1,409	9,146	3,206
<b>Swedish regions</b>	<b>15-44</b>	40	55	26	95	43	18	24	42	24	42	24	47	22	49	27	96	49	
	<b>45-54</b>	265	107	320	144	585	251	126	49	169	76	295	125	154	69	212	105	366	174
	<b>55-64</b>	612	211	517	220	1,129	431	382	149	363	169	745	318	637	258	764	331	1,401	589
	<b>65-74</b>	1,191	400	668	287	1,859	687	589	204	408	156	997	360	934	366	775	319	1,709	685
	<b>75-99</b>	915	213	542	153	1,457	366	552	116	375	107	927	223	885	271	731	225	1,616	496
	<b>Total</b>	3,023	948	2,102	830	5,125	1,778	1,667	524	1,339	523	3,006	1,047	2,657	986	2,531	1,007	5,188	1,993
<b>UK-England</b>	<b>15-44</b>	1,046	354	877	343	1,923	697	602	244	550	245	1,152	489	776	298	784	354	1,560	652
	<b>45-54</b>	5,660	1,725	3,794	1,307	9,454	3,032	3,118	970	2,507	926	5,625	1,896	3,510	1,170	3,129	1,240	6,639	2,410
	<b>55-64</b>	16,687	4,550	8,635	2,654	25,322	7,204	9,931	3,020	5,870	1,997	15,801	5,017	12,701	4,138	9,230	3,279	21,931	7,417
	<b>65-74</b>	34,890	7,819	19,574	4,482	54,464	12,301	18,358	4,613	10,946	2,969	29,304	7,582	20,910	6,147	14,008	4,440	34,918	10,587
	<b>75-99</b>	32,544	4,871	19,472	3,002	52,016	7,873	20,647	3,596	14,216	2,595	34,863	6,191	25,202	5,012	19,276	4,027	44,478	9,039
	<b>Total</b>	90,827	19,319	52,352	11,788	143,179	31,107	52,656	12,443	34,089	8,732	86,745	21,175	63,099	16,765	46,427	13,340	109,526	30,105
<b>UK-Northern Ireland</b>	<b>15-44</b>	46	19	28	74	31	13	6	18	11	31	17	32	14	30	16	62	30	
	<b>45-54</b>	186	64	131	38	317	102	109	39	77	21	186	59	131	50	113	37	244	87
	<b>55-64</b>	491	134	294	98	785	232	332	101	209	72	541	173	482	151	312	109	794	260
	<b>65-74</b>	1,079	264	598	162	1,677	426	597	158	354	71	951	229	744	201	460	145	1,204	346
	<b>75-99</b>	808	152	529	104	1,337	256	485	86	338	71	823	157	683	140	507	130	1,190	270
	<b>Total</b>	2,610	633	1,580	414	4,190	1,047	1,536	390	996	245	2,532	635	2,072	556	1,422	437	3,494	993
<b>UK-Wales</b>	<b>15-44</b>	49	18	60	28	109	46	33	14	29	62	26	56	22	46	20	102	42	
	<b>45-54</b>	340	99	276	99	616	198	204	59	165	71	369	130	238	75	244	105	482	180
	<b>55-64</b>	1,140	297	592	165	1,732	462	658	186	448	150	1,106	336	953	296	708	246	1,661	542
	<b>65-74</b>	2,372	477	1,345	270	3,717	747	1,265	293	792	198	2,057	491	1,513	430	1,003	295	2,516	725
	<b>75-99</b>	2,106	277	1,187	158	3,293	435	1,376	206	894	141	2,270	347	1,702	293	1,313	277	3,015	570
	<b>Total</b>	6,007	1,168	3,460	720	9,467	1,888	3,536	758	2,328	572	5,864	1,330	4,462	1,116	3,314	943	7,776	2,059

<sup>a</sup> No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

**Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: breast cancer (women)**

		1995-99		2000-02		2005-07 <sup>a</sup>	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	15-44	4,297	4,229	2,845	2,807	4,929	3,961
	45-54	7,487	7,361	4,885	4,802	8,525	6,734
	55-64	6,901	6,692	5,069	4,954	9,427	7,327
	65-74	6,562	6,242	4,115	3,931	6,790	5,274
	75-99	5,507	4,712	3,670	3,184	6,317	4,679
	<b>Total</b>	30,754	29,236	20,584	19,678	35,988	27,975
New South Wales	15-44	2,437	2,395	1,630	1,606	2,779	2,254
	45-54	4,264	4,193	2,776	2,730	4,858	3,819
	55-64	3,979	3,871	2,961	2,898	5,575	4,354
	65-74	3,712	3,531	2,356	2,241	3,861	3,006
	75-99	3,111	2,662	2,145	1,883	3,663	2,704
	<b>Total</b>	17,503	16,652	11,868	11,358	20,736	16,137
Victoria	15-44	1,860	1,834	1,215	1,201	2,150	1,707
	45-54	3,223	3,168	2,109	2,072	3,667	2,915
	55-64	2,922	2,821	2,108	2,056	3,852	2,973
	65-74	2,850	2,711	1,759	1,690	2,929	2,268
	75-99	2,396	2,050	1,525	1,301	2,654	1,975
	<b>Total</b>	13,251	12,584	8,716	8,320	15,252	11,838
Canadian registries	15-44	7,442	7,261	4,524	4,438	8,056	6,418
	45-54	12,213	11,930	8,445	8,271	14,797	11,619
	55-64	11,814	11,442	8,214	7,984	15,643	12,057
	65-74	12,616	11,945	7,533	7,197	13,020	9,989
	75-99	11,365	9,894	7,387	6,408	13,240	9,714
	<b>Total</b>	55,450	52,472	36,103	34,298	64,756	49,797
Alberta	15-44	1,112	1,085	671	650	1,207	944
	45-54	1,670	1,633	1,265	1,237	2,222	1,736
	55-64	1,569	1,524	1,120	1,093	2,043	1,566
	65-74	1,536	1,440	997	956	1,762	1,384
	75-99	1,407	1,213	1,000	860	1,778	1,323
	<b>Total</b>	7,294	6,895	5,053	4,796	9,012	6,953
British Columbia	15-44	1,505	1,469	904	895	1,604	1,274
	45-54	2,577	2,517	1,792	1,755	2,994	2,390
	55-64	2,494	2,419	1,647	1,600	3,228	2,476
	65-74	2,730	2,606	1,508	1,448	2,663	2,022
	75-99	2,651	2,382	1,626	1,412	2,860	2,094
	<b>Total</b>	11,957	11,393	7,477	7,110	13,349	10,256
Manitoba	15-44	390	377	221	216	351	267
	45-54	692	678	443	435	790	613
	55-64	695	671	482	468	896	701
	65-74	756	711	392	370	706	550
	75-99	847	745	523	463	917	676
	<b>Total</b>	3,380	3,182	2,061	1,952	3,660	2,807
Ontario	15-44	4,435	4,330	2,728	2,677	4,894	3,933
	45-54	7,274	7,102	4,945	4,844	8,791	6,880
	55-64	7,056	6,828	4,965	4,823	9,476	7,314
	65-74	7,594	7,188	4,636	4,423	7,889	6,033
	75-99	6,460	5,554	4,238	3,673	7,685	5,621
	<b>Total</b>	32,819	31,002	21,512	20,440	38,735	29,781



**Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: breast cancer (women)**

		1995-99		2000-02		2005-07 <sup>a</sup>	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
<b>Denmark</b>	<b>15-44</b>	1,788	1,744	1,126	1,104	1,945	1,566
	<b>45-54</b>	3,933	3,813	2,498	2,438	3,855	3,041
	<b>55-64</b>	4,129	3,913	3,062	2,918	5,694	4,420
	<b>65-74</b>	3,681	3,358	2,332	2,178	4,464	3,435
	<b>75-99</b>	3,783	3,029	2,588	2,111	4,389	3,120
	<b>Total</b>	17,314	15,857	11,606	10,749	20,347	15,582
<b>Norway</b>	<b>15-44</b>	1,323	1,280	828	810	1,498	1,174
	<b>45-54</b>	2,764	2,707	1,815	1,785	3,161	2,531
	<b>55-64</b>	2,437	2,350	2,162	2,116	3,896	3,075
	<b>65-74</b>	2,519	2,364	1,366	1,289	2,445	1,939
	<b>75-99</b>	2,994	2,538	1,858	1,573	3,121	2,304
	<b>Total</b>	12,037	11,239	8,029	7,573	14,121	11,023
<b>Swedish regions</b>	<b>15-44</b>	1,106	1,095	667	662	1,287	1,023
	<b>45-54</b>	2,843	2,809	1,622	1,614	2,569	2,077
	<b>55-64</b>	2,712	2,667	2,220	2,198	3,943	3,150
	<b>65-74</b>	2,452	2,368	1,535	1,497	2,766	2,137
	<b>75-99</b>	2,623	2,323	1,404	1,260	2,851	2,109
	<b>Total</b>	11,736	11,262	7,448	7,231	13,416	10,496
<b>UK-England</b>	<b>15-44</b>	17,899	17,277	11,476	11,164	20,545	16,368
	<b>45-54</b>	35,609	34,433	21,824	21,308	35,752	28,405
	<b>55-64</b>	34,083	32,375	24,064	23,181	45,629	35,979
	<b>65-74</b>	30,557	27,149	18,623	17,007	36,995	28,493
	<b>75-99</b>	37,373	28,012	24,124	18,767	41,505	28,907
	<b>Total</b>	155,521	139,246	100,111	91,427	180,426	138,152
<b>UK-Northern Ireland</b>	<b>15-44</b>	545	531	375	359	672	542
	<b>45-54</b>	1,061	1,031	623	594	1,148	883
	<b>55-64</b>	1,007	964	718	680	1,375	1,059
	<b>65-74</b>	838	766	502	471	950	722
	<b>75-99</b>	930	722	579	495	1,167	820
	<b>Total</b>	4,381	4,014	2,797	2,599	5,312	4,026
<b>UK-Wales</b>	<b>15-44</b>	992	955	631	609	1,075	858
	<b>45-54</b>	2,150	2,073	1,371	1,331	2,140	1,688
	<b>55-64</b>	2,074	1,969	1,566	1,478	3,050	2,414
	<b>65-74</b>	2,087	1,798	1,255	1,111	2,450	1,836
	<b>75-99</b>	2,597	1,864	1,606	1,182	2,731	1,878
	<b>Total</b>	9,900	8,659	6,429	5,711	11,446	8,674

<sup>a</sup> No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

**Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: ovarian cancer**

		1995-99		2000-02		2005-07 <sup>a</sup>	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
Australian registries	15-44	377	347	212	194	414	303
	45-54	572	501	351	316	652	480
	55-64	685	564	435	367	800	588
	65-74	831	605	457	316	789	530
	75-99	891	367	615	273	884	402
	<b>Total</b>	3,356	2,384	2,070	1,466	3,539	2,303
New South Wales	15-44	222	205	121	111	223	159
	45-54	320	272	203	182	388	293
	55-64	391	323	252	217	463	338
	65-74	450	320	256	179	427	290
	75-99	497	212	339	159	512	232
	<b>Total</b>	1,880	1,332	1,171	848	2,013	1,312
Victoria	15-44	155	142	91	83	191	144
	45-54	252	229	148	134	264	187
	55-64	294	241	183	150	337	250
	65-74	381	285	201	137	362	240
	75-99	394	155	276	114	372	170
	<b>Total</b>	1,476	1,052	899	618	1,526	991
Canadian registries	15-44	963	883	614	575	1,085	827
	45-54	1,357	1,171	930	829	1,614	1,168
	55-64	1,472	1,202	1,097	902	1,931	1,386
	65-74	1,969	1,409	1,093	813	1,876	1,239
	75-99	1,716	830	1,256	613	1,807	846
	<b>Total</b>	7,477	5,495	4,990	3,732	8,313	5,466
Alberta	15-44	206	194	100	91	109	80
	45-54	186	163	101	91	206	154
	55-64	175	143	122	97	193	142
	65-74	204	141	106	82	168	109
	75-99	201	80	123	49	187	78
	<b>Total</b>	972	721	552	410	863	563
British Columbia	15-44	148	132	86	83	156	120
	45-54	256	221	164	147	272	208
	55-64	242	209	179	161	321	237
	65-74	357	261	168	130	311	210
	75-99	350	177	237	108	312	140
	<b>Total</b>	1,353	1,000	834	629	1,372	915
Manitoba	15-44	48	39	27	26	46	32
	45-54	56	51	44	35	87	59
	55-64	79	66	51	42	103	77
	65-74	97	73	75	56	94	62
	75-99	117	41	80	44	104	44
	<b>Total</b>	397	270	277	202	434	274
Ontario	15-44	561	518	401	376	774	595
	45-54	859	736	621	556	1,049	747
	55-64	976	784	745	602	1,314	930
	65-74	1,311	934	744	545	1,303	858
	75-99	1,048	532	816	412	1,204	584
	<b>Total</b>	4,755	3,504	3,327	2,491	5,644	3,714

**Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: ovarian cancer**

		1995-99		2000-02		2005-07 <sup>a</sup>	
		All	1-year survivors	All	1-year survivors	All	1-year survivors
<b>Denmark</b>	<b>15-44</b>	275	238	161	149	199	152
	<b>45-54</b>	568	487	317	268	431	336
	<b>55-64</b>	716	550	452	366	774	540
	<b>65-74</b>	807	491	511	341	709	449
	<b>75-99</b>	667	239	426	172	577	243
	<b>Total</b>	3,033	2,005	1,867	1,296	2,690	1,720
<b>Norway</b>	<b>15-44</b>	234	220	144	134	174	141
	<b>45-54</b>	449	398	253	226	374	277
	<b>55-64</b>	476	407	348	312	631	472
	<b>65-74</b>	583	400	324	247	442	297
	<b>75-99</b>	643	270	427	188	571	280
	<b>Total</b>	2,385	1,695	1,496	1,107	2,192	1,467
<b>Swedish regions</b>	<b>15-44</b>						
	<b>45-54</b>						
	<b>55-64</b>						
	<b>65-74</b>						
	<b>75-99</b>						
	<b>Total</b>						
<b>UK-England</b>	<b>15-44</b>	2,741	2,437	1,588	1,458	2,852	2,132
	<b>45-54</b>	4,375	3,554	2,508	2,085	3,646	2,624
	<b>55-64</b>	5,898	4,166	3,891	2,975	6,229	4,298
	<b>65-74</b>	6,739	3,828	4,059	2,453	5,838	3,519
	<b>75-99</b>	6,272	2,160	4,423	1,511	5,790	2,252
	<b>Total</b>	26,025	16,145	16,469	10,482	24,355	14,825
<b>UK-Northern Ireland</b>	<b>15-44</b>	115	107	81	76	120	106
	<b>45-54</b>	163	125	84	68	135	103
	<b>55-64</b>	203	150	116	92	215	138
	<b>65-74</b>	206	123	132	92	204	125
	<b>75-99</b>	159	61	123	38	151	60
	<b>Total</b>	846	566	536	366	825	532
<b>UK-Wales</b>	<b>15-44</b>	166	146	100	90	163	124
	<b>45-54</b>	305	227	168	146	243	173
	<b>55-64</b>	424	283	276	208	448	291
	<b>65-74</b>	534	279	305	152	429	253
	<b>75-99</b>	497	172	312	112	414	152
	<b>Total</b>	1,926	1,107	1,161	708	1,697	993

<sup>a</sup> No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005

**Table 9: Mean age at diagnosis (and standard deviation): cancer, jurisdiction and calendar period of diagnosis**

	Calendar period					
	1995-1999		2000-2007		Overall	
	Mean	SD	Mean	SD	Mean	SD
<b>Colorectal</b>						
Alberta	69.6	12.7	69.0	13.0	69.2	12.9
British Columbia	70.5	12.1	70.4	12.6	70.4	12.4
Manitoba	70.5	12.4	70.5	13.0	70.5	12.8
Ontario	69.5	12.2	69.5	12.5	69.5	12.4
Denmark	71.1	11.8	70.9	11.7	71.0	11.8
Norway	71.7	11.7	71.8	12.3	71.8	12.1
Swedish regions	72.0	11.5	71.9	11.8	72.0	11.7
UK-England	71.4	11.8	71.7	12.0	71.6	11.9
UK-Northern Ireland	70.4	12.0	70.2	11.9	70.2	12.0
UK-Wales	71.3	11.7	71.5	11.7	71.4	11.7
New South Wales	68.9	12.2	69.6	12.3	69.4	12.3
Victoria	69.3	12.1	69.9	12.6	69.7	12.4
<b>Overall</b>	<b>70.8</b>	<b>11.9</b>	<b>71.0</b>	<b>12.2</b>	<b>70.9</b>	<b>12.1</b>
<b>Lung</b>						
Alberta	68.6	10.9	69.5	11.2	69.2	11.1
British Columbia	69.0	11.2	70.3	11.1	69.8	11.1
Manitoba	69.2	10.7	70.3	11.1	69.9	11.0
Ontario	68.3	10.8	69.2	11.1	68.9	11.0
Denmark	67.8	10.4	68.6	10.5	68.3	10.5
Norway	68.4	10.8	69.4	10.8	69.0	10.8
Swedish regions	68.1	10.5	68.9	10.6	68.6	10.6
UK-England	70.8	10.3	71.5	10.7	71.2	10.5
UK-Northern Ireland	69.8	10.3	70.0	10.4	69.9	10.4
UK-Wales	70.6	10.0	71.2	10.5	71.0	10.3
New South Wales	69.3	10.6	70.2	11.1	69.9	10.9
Victoria	69.8	10.5	70.7	11.1	70.4	10.9
<b>Overall</b>	<b>69.9</b>	<b>10.5</b>	<b>70.6</b>	<b>10.8</b>	<b>70.3</b>	<b>10.7</b>
<b>Breast</b>						
Alberta	60.9	14.5	61.1	14.3	61.0	14.4
British Columbia	62.3	14.3	62.1	14.2	62.2	14.3
Manitoba	63.4	14.5	63.5	14.5	63.4	14.5
Ontario	61.6	14.3	61.6	14.1	61.6	14.1
Denmark	62.6	14.0	63.1	13.8	62.9	13.9
Norway	63.2	14.6	62.4	14.3	62.7	14.4
Swedish regions	62.7	13.9	62.7	13.6	62.7	13.7
UK-England	62.8	14.8	63.1	14.6	63.0	14.7
UK-Northern Ireland	61.6	14.6	62.0	14.6	61.8	14.6
UK-Wales	63.9	14.7	64.0	14.3	63.9	14.5
New South Wales	60.6	14.0	60.7	13.9	60.6	14.0
Victoria	60.7	14.2	60.5	14.1	60.6	14.1
<b>Overall</b>	<b>62.4</b>	<b>14.6</b>	<b>62.5</b>	<b>14.4</b>	<b>62.5</b>	<b>14.4</b>
<b>Ovary</b>						
Alberta	59.7	16.7	62.0	15.7	61.1	16.1
British Columbia	63.9	15.3	63.9	15.4	63.9	15.3
Manitoba	64.9	15.7	64.7	15.4	64.8	15.5
Ontario	63.0	14.7	62.9	15.3	62.9	15.1
Denmark	63.4	13.7	64.6	13.5	64.2	13.6
Norway	64.3	14.4	65.0	14.6	64.7	14.6
Swedish regions	-	-	-	-	-	-
UK-England	63.7	14.8	64.6	15.0	64.3	14.9
UK-Northern Ireland	61.3	15.1	62.6	15.5	62.1	15.4
UK-Wales	64.9	14.1	65.4	14.4	65.2	14.3
New South Wales	63.4	15.4	63.9	15.6	63.7	15.5
Victoria	64.2	15.3	64.5	15.5	64.4	15.4
<b>Overall</b>	<b>63.6</b>	<b>14.8</b>	<b>64.3</b>	<b>15.0</b>	<b>64.0</b>	<b>14.9</b>

Swedish regions - no ovarian cancer data

**Table 10: Number and percentage of adults (15-99 years) diagnosed during 1995-2007 whose cancer was a second or higher-order primary: by cancer and jurisdiction**

	Colorectal cancer			Breast cancer		
	Second and higher-order primaries		All primaries	Second and higher-order primaries		All primaries
	No.	%		No.	%	
Alberta	2,240	13.0	17,263	1,848	8.7	21,255
British Columbia	4,161	14.6	28,418	3,241	9.9	32,648
Manitoba	1,319	14.8	8,918	995	11.0	9,061
Ontario	6,823	8.1	84,362	4,508	4.9	92,597
Denmark	3,658	7.9	46,183	2,689	5.5	49,001
Norway	4,920	12.0	40,909	2,808	8.3	34,001
Swedish regions	2,961	12.6	23,554	2,844	8.8	32,395
UK-England	21,820	6.2	352,801	18,198	4.2	435,247
UK-Northern Ireland	417	3.5	11,891	227	1.8	12,464
UK-Wales	1,955	7.9	24,882	1,277	4.6	27,828
New South Wales	3,311	6.3	52,303	1,154	2.3	49,832
Victoria	5,049	12.5	40,521	2,009	5.4	37,021
<b>Overall</b>	<b>58,634</b>	<b>8.0</b>	<b>732,005</b>	<b>41,798</b>	<b>5.0</b>	<b>833,350</b>

  

	Lung cancer			Ovarian cancer		
	Second and higher-order primaries		All primaries	Second and higher-order primaries		All primaries
	No.	%		No.	%	
Alberta	2,756	14.5	19,031	294	12.0	2,454
British Columbia	4,579	14.7	31,123	377	10.4	3,640
Manitoba	1,646	17.9	9,202	155	13.5	1,146
Ontario	7,793	8.7	89,963	1,182	8.5	13,970
Denmark	4,173	8.9	47,151	652	8.4	7,773
Norway	3,321	12.1	27,383	664	10.8	6,159
Swedish regions	1,769	12.1	14,605	-	-	-
UK-England	28,109	7.5	376,496	4,741	6.8	69,485
UK-Northern Ireland	462	4.1	11,356	144	6.3	2,296
UK-Wales	2,465	9.6	25,742	490	9.8	5,003
New South Wales	2,635	7.3	36,251	316	6.1	5,151
Victoria	3,772	14.0	27,027	422	10.6	3,982
<b>Overall</b>	<b>63,480</b>	<b>8.9</b>	<b>715,330</b>	<b>9,437</b>	<b>7.8</b>	<b>121,059</b>

Swedish regions - no ovarian cancer data

**Table 11: Number and percentage of patients dying within a month of diagnosis, by period of diagnosis and**

	1995-1999		2000-2007		Overall	
	No.	%	No.	%	No.	%
<b>Colorectal</b>						
Alberta	398	7.0	777	6.8	1,175	6.9
British Columbia	500	5.1	983	5.3	1,483	5.3
Manitoba	184	5.7	321	5.7	505	5.7
Ontario	2,732	9.4	4,388	8.0	7,120	8.5
Denmark <sup>1</sup>	-	-	1,252	8.1	1,252	8.1
Norway	746	5.1	1,517	5.8	2,263	5.6
Swedish regions	343	4.6	643	4.0	986	4.2
UK-England	16,383	12.6	22,111	10.0	38,494	11.0
UK-Northern Ireland	391	8.8	506	6.9	897	7.6
UK-Wales	1,173	12.5	1,521	9.9	2,694	10.9
New South Wales <sup>2</sup>	-	-	-	-	-	-
Victoria	834	5.8	1,197	4.6	2,031	5.0
<b>Overall</b>	<b>23,684</b>	<b>10.4</b>	<b>35,216</b>	<b>8.4</b>	<b>58,900</b>	<b>9.1</b>
<b>Overall excluding New South Wales and Denmark</b>	<b>23,684</b>	<b>10.4</b>	<b>33,964</b>	<b>8.5</b>	<b>57,648</b>	<b>9.2</b>
<b>Lung</b>						
Alberta	1,246	19.1	2,406	19.4	3,652	19.3
British Columbia	1,834	16.4	3,124	15.8	4,958	16.0
Manitoba	410	13.2	896	14.9	1,306	14.3
Ontario	7,776	23.9	13,951	24.5	21,727	24.3
Denmark <sup>1</sup>	-	-	2,499	15.9	2,499	15.9
Norway	1,304	13.9	2,748	15.4	4,052	14.9
Swedish regions	828	16.2	1,046	11.1	1,874	12.8
UK-England	37,635	26.3	53,415	23.1	91,050	24.3
UK-Northern Ireland	904	21.6	1,457	20.5	2,361	20.9
UK-Wales	2,812	29.7	3,923	24.3	6,735	26.3
New South Wales <sup>2</sup>	-	-	-	-	-	-
Victoria	1,409	14.4	2,472	14.5	3,881	14.5
<b>Overall</b>	<b>56,158</b>	<b>24.0</b>	<b>87,937</b>	<b>21.4</b>	<b>144,095</b>	<b>22.4</b>
<b>Overall excluding New South Wales and Denmark</b>	<b>56,158</b>	<b>24.0</b>	<b>85,438</b>	<b>21.7</b>	<b>141,596</b>	<b>22.5</b>
<b>Breast</b>						
Alberta	83	1.1	118	0.9	201	1.0
British Columbia	86	0.7	171	0.8	257	0.8
Manitoba	25	0.7	47	0.8	72	0.8
Ontario	565	1.7	883	1.5	1,448	1.6
Denmark <sup>1</sup>	-	-	156	1.0	156	1.0
Norway	90	0.7	180	0.8	270	0.8
Swedish regions	43	0.4	50	0.2	93	0.3
UK-England	5,279	3.4	5,686	2.1	10,965	2.5
UK-Northern Ireland	77	1.8	88	1.1	165	1.3
UK-Wales	424	4.3	491	2.8	915	3.3
New South Wales <sup>2</sup>	-	-	-	-	-	-
Victoria	148	1.1	215	0.9	363	1.0
<b>Overall</b>	<b>6,820</b>	<b>2.6</b>	<b>8,085</b>	<b>1.7</b>	<b>14,905</b>	<b>2.0</b>
<b>Overall excluding New South Wales and Denmark</b>	<b>6,820</b>	<b>2.6</b>	<b>7,929</b>	<b>1.7</b>	<b>14,749</b>	<b>2.0</b>
<b>Ovary</b>						
Alberta	86	8.9	127	8.7	213	8.7
British Columbia	107	7.9	180	7.9	287	7.9
Manitoba	37	9.3	75	10.1	112	9.9
Ontario	497	10.5	892	9.8	1,389	10.0
Denmark <sup>1</sup>	-	-	156	6.9	156	6.9
Norway	139	5.8	246	6.6	385	6.3
Swedish regions	-	-	-	-	-	-
UK-England	3,275	12.6	5,142	11.9	8,417	12.2
UK-Northern Ireland	90	10.6	138	9.6	228	10.0
UK-Wales	246	12.8	394	12.9	640	12.9
New South Wales <sup>2</sup>	-	-	-	-	-	-
Victoria	130	8.8	193	7.8	323	8.2
<b>Overall</b>	<b>4,607</b>	<b>11.5</b>	<b>7,543</b>	<b>10.8</b>	<b>12,150</b>	<b>11.1</b>
<b>Overall excluding New South Wales and Denmark</b>	<b>4,607</b>	<b>11.5</b>	<b>7,387</b>	<b>11.0</b>	<b>11,994</b>	<b>11.2</b>

<sup>1</sup> Full dates were only collected from 2004 onwards

<sup>2</sup> Full dates were not collected by this registry

<sup>3</sup> Swedish regions - no ovarian cancer data

**Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 1995-99**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Colorectal cancer (persons)</b>																
<b>One year</b>	<b>No. of patients</b>	32,621	18,358	14,263	47,832	5,661	9,736	3,254	29,181	16,393	14,703	7,382	144,088	130,276	4,430	9,382
	<b>Age-standardised</b>	<b>80.0</b>	<b>80.3</b>	<b>79.6</b>	<b>79.1</b>	<b>77.6</b>	<b>80.7</b>	<b>79.8</b>	<b>78.7</b>	<b>71.7</b>	<b>78.6</b>	<b>81.8</b>	<b>70.2</b>	<b>70.2</b>	<b>74.3</b>	<b>68.3</b>
	<b>15-44 years</b>	87.0	87.6	86.3	83.7	81.3	85.6	86.2	83.4	82.8	83.3	86.4	80.6	80.6	83.2	78.8
	<b>45-54 years</b>	85.8	84.8	87.2	84.5	82.6	83.9	83.1	85.3	78.2	83.7	87.1	80.2	80.1	82.9	80.1
	<b>55-64 years</b>	83.6	83.7	83.4	83.1	80.8	84.2	86.4	82.9	77.3	83.6	82.7	77.4	77.3	81.8	75.7
	<b>65-74 years</b>	80.9	81.7	79.9	80.1	80.0	82.3	79.8	79.4	71.8	79.9	82.9	71.2	71.2	74.7	68.8
	<b>75-99 years</b>	72.1	72.6	71.4	71.5	69.7	73.9	71.7	70.9	62.0	70.2	76.6	57.0	57.0	62.2	54.6
<b>Five years</b>	<b>Age-standardised</b>	<b>60.0</b>	<b>61.2</b>	<b>58.4</b>	<b>58.1</b>	<b>56.3</b>	<b>59.8</b>	<b>57.6</b>	<b>58.0</b>	<b>48.2</b>	<b>56.9</b>	<b>58.5</b>	<b>47.8</b>	<b>47.8</b>	<b>51.1</b>	<b>45.9</b>
	<b>15-44 years</b>	66.2	69.2	62.6	60.8	58.5	60.2	67.5	60.8	58.0	58.4	60.6	56.4	56.6	55.3	54.2
	<b>45-54 years</b>	63.9	63.7	64.1	61.4	58.8	61.7	57.1	62.3	50.7	57.0	60.8	53.2	53.1	57.4	52.8
	<b>55-64 years</b>	62.4	63.2	61.3	59.6	58.5	59.5	58.6	59.9	49.9	62.1	60.3	52.4	52.3	56.2	51.7
	<b>65-74 years</b>	60.9	62.4	59.1	59.3	59.7	62.1	59.3	58.3	48.9	59.0	59.2	48.4	48.5	52.0	44.7
	<b>75-99 years</b>	53.9	55.5	52.1	53.9	49.4	56.9	52.8	53.8	42.7	50.2	55.0	39.2	39.2	42.6	37.6
<b>Conditional 5-year</b>	<b>No. of patients</b>	24,926	14,094	10,832	36,002	4,168	7,448	2,443	21,943	10,851	10,733	5,666	92,915	83,994	3,053	5,868
	<b>Age-standardised</b>	<b>75.0</b>	<b>76.2</b>	<b>73.4</b>	<b>73.6</b>	<b>72.5</b>	<b>74.2</b>	<b>72.2</b>	<b>73.8</b>	<b>67.3</b>	<b>72.3</b>	<b>71.6</b>	<b>68.1</b>	<b>68.2</b>	<b>68.8</b>	<b>67.2</b>
	<b>15-44 years</b>	76.1	79.1	72.6	72.6	71.9	70.3	78.3	72.9	70.1	70.1	70.2	70.0	70.2	66.5	68.8
	<b>45-54 years</b>	74.4	75.1	73.5	72.7	71.1	73.5	68.8	73.1	64.9	68.1	69.9	66.4	66.4	69.3	65.9
	<b>55-64 years</b>	74.6	75.5	73.4	71.7	72.4	70.6	67.8	72.3	64.5	74.3	72.9	67.7	67.7	68.7	68.3
	<b>65-74 years</b>	75.3	76.3	74.0	74.1	74.7	75.4	74.4	73.5	68.2	73.8	71.4	68.0	68.1	69.6	65.0
	<b>75-99 years</b>	74.8	76.3	72.9	75.3	70.9	76.9	73.6	75.8	68.8	71.6	71.8	68.8	68.8	68.6	68.8
<b>Lung cancer (persons)</b>																
<b>One year</b>	<b>No. of patients</b>	22,827	13,072	9,755	53,316	6,513	11,158	3,114	32,531	16,484	9,413	5,125	156,836	143,179	4,190	9,467
	<b>Age-standardised</b>	<b>38.2</b>	<b>38.6</b>	<b>37.8</b>	<b>38.7</b>	<b>36.4</b>	<b>36.6</b>	<b>41.7</b>	<b>39.6</b>	<b>26.4</b>	<b>32.3</b>	<b>35.7</b>	<b>24.3</b>	<b>24.3</b>	<b>27.4</b>	<b>23.0</b>
	<b>15-44 years</b>	55.1	53.5	57.7	46.7	41.1	45.5	47.4	48.0	37.1	51.0	45.5	36.7	36.2	42.2	42.5
	<b>45-54 years</b>	43.4	43.9	42.9	44.4	41.2	41.0	42.2	46.3	35.6	40.8	42.9	32.1	32.1	32.5	32.2
	<b>55-64 years</b>	43.1	42.9	43.4	42.9	41.1	40.8	44.3	43.7	31.8	36.2	38.3	28.6	28.6	30.0	26.9
	<b>65-74 years</b>	38.2	38.6	37.6	38.9	35.7	37.8	40.7	39.7	25.5	30.2	37.8	23.0	23.1	26.1	20.4
	<b>75-99 years</b>	28.2	29.5	26.7	31.1	30.3	27.9	39.2	31.4	16.7	23.3	26.3	16.0	16.1	20.9	13.9
<b>Five years</b>	<b>Age-standardised</b>	<b>13.9</b>	<b>14.2</b>	<b>13.4</b>	<b>15.7</b>	<b>13.8</b>	<b>13.9</b>	<b>16.6</b>	<b>16.6</b>	<b>8.0</b>	<b>11.0</b>	<b>12.7</b>	<b>7.0</b>	<b>6.9</b>	<b>9.7</b>	<b>7.5</b>
	<b>15-44 years</b>	28.6	26.3	32.2	23.8	21.4	21.8	29.3	24.6	19.7	27.5	17.2	18.0	17.4	27.4	22.5
	<b>45-54 years</b>	17.4	18.4	16.1	20.2	18.1	16.9	18.2	22.0	11.1	16.0	16.7	10.2	10.0	10.6	12.8
	<b>55-64 years</b>	15.9	16.0	15.8	18.1	17.2	16.6	19.3	18.7	9.9	12.4	14.4	8.7	8.7	9.7	8.9
	<b>65-74 years</b>	13.1	14.0	11.9	15.2	13.4	14.3	13.6	16.0	7.1	9.6	12.8	5.9	5.9	8.7	5.5
	<b>75-99 years</b>	8.0	8.4	7.4	10.4	7.9	8.2	13.9	11.4	3.4	5.2	8.5	2.9	2.8	5.9	2.5
<b>Conditional 5-year</b>	<b>No. of patients</b>	8,010	4,596	3,414	19,781	2,202	3,886	1,244	12,449	4,180	2,839	1,778	34,042	31,107	1,047	1,888
	<b>Age-standardised</b>	<b>35.1</b>	<b>35.9</b>	<b>34.0</b>	<b>39.9</b>	<b>37.0</b>	<b>37.2</b>	<b>39.5</b>	<b>41.3</b>	<b>28.6</b>	<b>32.1</b>	<b>35.1</b>	<b>26.9</b>	<b>26.6</b>	<b>33.8</b>	<b>29.2</b>
	<b>15-44 years</b>	51.9	49.2	55.9	51.0	52.0	48.0	61.8	51.2	53.2	53.9	37.8	48.9	47.9	65.0	52.9
	<b>45-54 years</b>	40.0	41.9	37.6	45.6	43.8	41.3	43.3	47.4	31.2	39.1	38.9	31.9	31.3	32.6	39.9
	<b>55-64 years</b>	36.9	37.3	36.4	42.3	41.8	40.7	43.4	42.7	31.2	34.2	37.4	30.5	30.2	32.4	33.0
	<b>65-74 years</b>	34.3	36.3	31.6	39.2	37.6	37.9	33.4	40.3	28.0	31.8	33.8	25.8	25.5	33.2	26.9
	<b>75-99 years</b>	28.3	28.6	27.8	33.6	26.2	29.4	35.6	36.3	20.3	22.5	32.3	17.9	17.5	28.5	18.3

**Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 1995-99**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Breast cancer (women)</b>																
<b>One year</b>	<b>No. of patients</b>	30,754	17,503	13,251	55,450	7,294	11,957	3,380	32,819	17,314	12,037	11,736	169,802	155,521	4,381	9,900
	<b>Age-standardised</b>	<b>95.8</b>	<b>95.8</b>	<b>95.6</b>	<b>95.9</b>	<b>95.4</b>	<b>97.1</b>	<b>96.2</b>	<b>95.5</b>	<b>93.0</b>	<b>95.4</b>	<b>97.6</b>	<b>90.4</b>	<b>90.5</b>	<b>92.6</b>	<b>88.6</b>
	<b>15-44 years</b>	98.5	98.4	98.7	97.7	97.7	97.7	96.7	97.7	97.7	96.8	99.1	96.6	96.6	97.5	96.4
	<b>45-54 years</b>	98.5	98.6	98.5	97.9	98.1	97.9	98.2	97.9	97.3	98.2	99.0	97.0	97.0	97.5	96.7
	<b>55-64 years</b>	97.5	97.9	97.1	97.5	97.8	97.6	97.2	97.4	95.7	97.0	98.9	95.7	95.7	96.6	95.7
	<b>65-74 years</b>	96.7	96.7	96.6	96.4	95.3	97.2	95.8	96.4	93.5	95.6	98.2	90.7	90.8	93.6	88.0
	<b>75-99 years</b>	91.6	91.6	91.7	93.0	92.0	96.0	94.8	91.6	87.6	92.6	95.1	81.6	81.7	85.3	78.4
<b>Five years</b>	<b>Age-standardised</b>	<b>85.0</b>	<b>85.5</b>	<b>84.4</b>	<b>85.3</b>	<b>83.4</b>	<b>87.1</b>	<b>86.0</b>	<b>84.9</b>	<b>76.9</b>	<b>81.8</b>	<b>86.7</b>	<b>74.8</b>	<b>74.8</b>	<b>77.5</b>	<b>73.5</b>
	<b>15-44 years</b>	84.3	84.6	83.9	82.4	82.9	80.7	79.7	83.0	79.5	80.5	83.9	78.3	78.3	79.7	77.8
	<b>45-54 years</b>	88.2	88.4	88.0	87.3	87.3	88.1	87.5	87.0	83.4	86.1	89.7	84.3	84.3	84.0	84.4
	<b>55-64 years</b>	88.4	89.0	87.5	87.1	87.0	87.2	85.9	87.2	80.9	85.6	90.6	83.1	83.1	83.4	83.1
	<b>65-74 years</b>	88.0	88.2	87.8	87.1	84.5	89.1	88.7	86.8	77.7	83.4	88.8	75.1	75.2	76.2	72.4
	<b>75-99 years</b>	78.3	79.0	77.3	81.9	77.9	86.1	84.2	80.7	69.7	75.6	81.0	63.0	62.9	70.8	61.5
<b>Conditional 5-year</b>	<b>No. of patients</b>	29,236	16,652	12,584	52,472	6,895	11,393	3,182	31,002	15,857	11,239	11,262	151,919	139,246	4,014	8,659
	<b>Age-standardised</b>	<b>88.8</b>	<b>89.1</b>	<b>88.2</b>	<b>88.9</b>	<b>87.3</b>	<b>89.7</b>	<b>89.4</b>	<b>88.9</b>	<b>82.6</b>	<b>85.6</b>	<b>88.8</b>	<b>82.5</b>	<b>82.4</b>	<b>83.6</b>	<b>82.7</b>
	<b>15-44 years</b>	85.6	86.0	85.0	84.3	84.9	82.6	82.4	85.0	81.4	83.1	84.6	81.0	81.0	81.8	80.8
	<b>45-54 years</b>	89.5	89.7	89.4	89.2	89.0	90.0	89.0	88.9	85.7	87.7	90.6	86.9	86.9	86.2	87.3
	<b>55-64 years</b>	90.6	90.9	90.2	89.4	89.0	89.3	88.4	89.6	84.5	88.2	91.6	86.8	86.8	86.3	86.9
	<b>65-74 years</b>	91.0	91.1	90.9	90.4	88.6	91.7	92.5	90.1	83.1	87.3	90.5	82.8	82.9	81.4	82.2
	<b>75-99 years</b>	85.4	86.2	84.3	88.1	84.7	89.7	88.8	88.1	79.6	81.6	85.2	77.2	77.0	83.0	78.4
<b>Ovarian cancer</b>																
<b>One year</b>	<b>No. of patients</b>	3,356	1,880	1,476	7,477	972	1,353	397	4,755	3,033	2,385	-	28,797	26,025	846	1,926
	<b>Age-standardised</b>	<b>70.4</b>	<b>70.4</b>	<b>70.4</b>	<b>71.8</b>	<b>69.4</b>	<b>74.0</b>	<b>68.9</b>	<b>71.9</b>	<b>63.4</b>	<b>70.4</b>	-	<b>59.6</b>	<b>59.8</b>	<b>62.8</b>	<b>56.6</b>
	<b>15-44 years</b>	92.1	92.4	91.7	91.8	94.3	89.3	81.2	92.4	86.6	94.1	-	89.1	89.0	93.1	88.0
	<b>45-54 years</b>	87.8	85.3	91.0	86.5	87.9	86.5	91.2	85.9	86.1	88.9	-	80.9	81.5	77.0	74.7
	<b>55-64 years</b>	82.9	83.2	82.4	82.2	82.4	87.0	84.1	80.9	77.6	86.1	-	71.0	71.2	74.5	67.3
	<b>65-74 years</b>	74.1	72.6	76.0	72.9	71.0	74.5	76.4	72.5	62.3	69.9	-	57.7	57.9	61.2	53.2
	<b>75-99 years</b>	44.4	46.5	41.7	51.4	43.9	54.3	37.1	53.4	38.4	45.0	-	36.6	36.5	41.8	36.5
<b>Five years</b>	<b>Age-standardised</b>	<b>36.1</b>	<b>35.9</b>	<b>36.4</b>	<b>38.2</b>	<b>41.4</b>	<b>35.1</b>	<b>32.7</b>	<b>39.0</b>	<b>31.5</b>	<b>37.2</b>	-	<b>32.6</b>	<b>32.5</b>	<b>39.0</b>	<b>31.5</b>
	<b>15-44 years</b>	73.0	71.0	75.9	74.0	84.5	65.9	56.4	73.7	62.3	72.6	-	73.0	73.0	73.5	72.1
	<b>45-54 years</b>	53.5	53.1	54.0	53.8	58.6	52.9	48.8	53.4	45.5	53.7	-	48.3	48.4	48.0	47.3
	<b>55-64 years</b>	43.3	42.1	44.8	43.9	44.7	46.0	41.8	43.4	36.9	46.8	-	36.5	36.5	41.7	33.0
	<b>65-74 years</b>	34.7	35.7	33.6	33.2	39.3	27.0	36.5	33.8	27.2	33.3	-	27.4	27.1	39.1	27.4
	<b>75-99 years</b>	15.8	15.8	15.7	23.5	23.4	19.8	9.1	26.4	18.4	18.1	-	18.4	18.3	24.5	17.9
<b>Conditional 5-year</b>	<b>No. of patients</b>	2,384	1,332	1,052	5,495	721	1,000	270	3,504	2,005	1,695	-	17,818	16,145	566	1,107
	<b>Age-standardised</b>	<b>48.8</b>	<b>48.6</b>	<b>49.2</b>	<b>51.9</b>	<b>58.3</b>	<b>45.7</b>	<b>43.7</b>	<b>53.3</b>	<b>48.9</b>	<b>50.6</b>	-	<b>53.1</b>	<b>52.8</b>	<b>63.0</b>	<b>53.8</b>
	<b>15-44 years</b>	79.3	76.9	82.7	80.6	89.7	73.9	69.5	79.7	71.9	77.2	-	81.9	82.1	79.0	81.9
	<b>45-54 years</b>	60.9	62.2	59.3	62.2	66.6	61.1	53.5	62.2	52.9	60.5	-	59.7	59.4	62.4	63.3
	<b>55-64 years</b>	52.2	50.6	54.4	53.4	54.3	52.8	49.7	53.6	47.6	54.3	-	51.4	51.3	56.0	49.1
	<b>65-74 years</b>	46.9	49.2	44.3	45.6	55.4	36.2	47.8	46.6	43.7	47.7	-	47.6	46.8	63.9	51.5
	<b>75-99 years</b>	35.5	33.9	37.7	45.7	53.4	36.4	24.6	49.5	48.0	40.2	-	50.3	50.0	64.2	49.1

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)



**Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 2000-02**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Colorectal cancer (persons)</b>																
<b>One year</b>	<b>No. of patients</b>	21,665	12,075	9,590	32,749	4,027	6,759	2,095	19,868	10,436	9,518	5,786	88,999	80,838	2,590	5,571
	<b>Age-standardised</b>	<b>82.5</b>	<b>83.2</b>	<b>81.6</b>	<b>81.5</b>	<b>79.8</b>	<b>82.4</b>	<b>80.4</b>	<b>81.7</b>	<b>73.9</b>	<b>78.7</b>	<b>82.8</b>	<b>73.0</b>	<b>72.9</b>	<b>76.8</b>	<b>72.3</b>
	<b>15-44 years</b>	90.8	92.0	89.5	88.0	85.6	89.5	81.4	88.8	82.1	86.2	88.6	84.4	84.0	89.1	86.8
	<b>45-54 years</b>	87.9	88.3	87.5	87.3	84.1	86.7	90.1	87.9	84.5	83.2	85.7	81.7	81.6	84.3	81.6
	<b>55-64 years</b>	87.3	88.4	85.7	85.9	85.5	86.1	80.0	86.5	82.5	85.0	86.8	80.4	80.4	83.3	77.9
	<b>65-74 years</b>	83.5	83.9	82.9	82.6	81.5	82.8	84.1	82.6	72.9	79.7	83.1	74.3	74.2	77.7	73.6
	<b>75-99 years</b>	73.5	74.1	72.8	73.0	70.5	75.4	72.8	72.6	61.7	69.0	76.9	59.4	59.2	64.5	59.1
<b>Five years</b>	<b>Age-standardised</b>	<b>63.4</b>	<b>65.1</b>	<b>61.1</b>	<b>60.9</b>	<b>58.0</b>	<b>61.5</b>	<b>59.6</b>	<b>61.3</b>	<b>51.7</b>	<b>58.8</b>	<b>60.6</b>	<b>51.3</b>	<b>51.2</b>	<b>54.3</b>	<b>50.3</b>
	<b>15-44 years</b>	69.0	71.6	66.1	63.8	63.7	65.6	57.9	63.9	60.1	68.0	64.5	59.5	59.0	64.8	64.6
	<b>45-54 years</b>	66.6	68.6	64.1	63.8	59.8	62.6	68.1	64.6	57.3	62.5	59.5	56.3	56.4	58.4	54.4
	<b>55-64 years</b>	67.9	69.5	65.6	64.2	62.6	63.5	60.7	65.1	56.0	62.3	64.0	56.3	56.6	55.1	52.9
	<b>65-74 years</b>	64.9	67.0	62.2	62.4	62.4	62.5	63.8	62.1	50.5	58.8	60.2	52.5	52.5	55.1	51.7
	<b>75-99 years</b>	55.5	56.7	54.1	54.8	47.8	57.5	51.6	55.6	45.1	52.1	57.9	41.9	41.7	48.8	41.8
<b>Conditional 5-year</b>	<b>No. of patients</b>	17,004	9,566	7,438	25,409	3,073	5,269	1,591	15,476	7,112	6,918	4,503	59,437	53,885	1,864	3,688
	<b>Age-standardised</b>	<b>76.7</b>	<b>78.2</b>	<b>74.9</b>	<b>74.7</b>	<b>72.5</b>	<b>74.8</b>	<b>74.0</b>	<b>75.2</b>	<b>70.1</b>	<b>74.7</b>	<b>73.3</b>	<b>70.3</b>	<b>70.3</b>	<b>71.1</b>	<b>69.7</b>
	<b>15-44 years</b>	76.0	77.9	73.8	72.5	74.5	73.3	71.1	72.0	73.2	78.9	72.7	70.6	70.2	72.7	74.4
	<b>45-54 years</b>	75.7	77.7	73.3	73.1	71.1	72.2	75.6	73.5	67.8	75.1	69.4	68.9	69.1	69.3	66.7
	<b>55-64 years</b>	77.8	78.6	76.6	74.7	73.2	73.8	75.8	75.3	67.9	73.3	73.8	70.1	70.4	66.2	67.9
	<b>65-74 years</b>	77.7	79.8	75.1	75.5	76.5	75.5	75.9	75.2	69.2	73.8	72.5	70.7	70.7	70.9	70.2
	<b>75-99 years</b>	75.5	76.5	74.3	75.0	67.9	76.3	70.8	76.5	73.1	75.6	75.4	70.6	70.5	75.6	70.8
<b>Lung cancer (persons)</b>																
<b>One year</b>	<b>No. of patients</b>	14,306	8,228	6,078	34,156	4,264	6,977	2,113	20,802	10,972	6,250	3,006	95,141	86,745	2,532	5,864
	<b>Age-standardised</b>	<b>40.9</b>	<b>41.5</b>	<b>39.9</b>	<b>39.7</b>	<b>36.3</b>	<b>37.5</b>	<b>44.1</b>	<b>40.5</b>	<b>31.3</b>	<b>32.2</b>	<b>36.6</b>	<b>27.5</b>	<b>27.5</b>	<b>28.3</b>	<b>25.9</b>
	<b>15-44 years</b>	55.2	58.9	49.5	51.3	39.7	50.7	51.1	53.4	48.6	45.7	49.6	42.9	42.5	55.4	42.3
	<b>45-54 years</b>	49.6	49.8	49.2	44.6	37.5	42.1	47.4	46.7	39.3	41.1	42.5	33.8	33.8	31.8	35.3
	<b>55-64 years</b>	44.8	44.9	44.6	43.4	39.8	39.6	44.6	45.2	37.3	36.0	43.1	31.9	32.0	32.5	30.6
	<b>65-74 years</b>	40.0	40.6	39.3	40.1	38.1	38.7	45.1	40.5	30.1	32.3	36.8	26.2	26.4	24.8	24.3
	<b>75-99 years</b>	31.5	32.2	30.7	31.3	30.5	29.6	39.7	31.0	20.4	22.3	25.7	18.8	18.9	20.5	16.1
<b>Five years</b>	<b>Age-standardised</b>	<b>15.1</b>	<b>16.2</b>	<b>13.6</b>	<b>15.9</b>	<b>13.1</b>	<b>14.0</b>	<b>19.4</b>	<b>16.7</b>	<b>9.6</b>	<b>11.0</b>	<b>11.6</b>	<b>8.1</b>	<b>8.0</b>	<b>9.7</b>	<b>7.6</b>
	<b>15-44 years</b>	32.0	34.1	29.0	25.1	19.8	22.2	17.3	27.4	22.2	0.0	0.0	21.5	21.3	32.9	19.8
	<b>45-54 years</b>	19.8	21.3	17.4	20.2	17.1	18.0	19.4	21.6	13.1	17.0	14.4	10.3	10.2	11.0	11.2
	<b>55-64 years</b>	15.6	15.7	15.5	17.9	14.9	14.8	21.7	18.9	11.1	13.8	15.3	9.5	9.6	10.7	8.6
	<b>65-74 years</b>	14.2	15.6	12.4	15.4	12.7	14.6	21.0	15.7	8.8	10.8	10.8	7.1	7.1	7.8	6.3
	<b>75-99 years</b>	9.6	10.8	8.0	10.8	8.8	8.9	16.7	11.2	4.8	4.9	7.4	3.7	3.7	4.8	3.7
<b>Conditional 5-year</b>	<b>No. of patients</b>	5,323	3,074	2,249	12,826	1,436	2,456	887	8,047	3,224	1,882	1,047	23,140	21,175	635	1,330
	<b>Age-standardised</b>	<b>36.0</b>	<b>38.1</b>	<b>33.0</b>	<b>39.4</b>	<b>35.6</b>	<b>36.5</b>	<b>44.2</b>	<b>40.5</b>	<b>29.4</b>	<b>32.8</b>	<b>31.5</b>	<b>27.6</b>	<b>27.4</b>	<b>31.8</b>	<b>27.7</b>
	<b>15-44 years</b>	58.1	57.8	58.6	49.0	49.9	43.8	33.9	51.3	45.7	0.0	0.0	50.2	50.0	59.4	46.7
	<b>45-54 years</b>	40.0	42.8	35.5	45.2	45.7	42.6	40.9	46.3	33.4	41.4	33.8	30.4	30.2	34.5	31.7
	<b>55-64 years</b>	34.8	34.9	34.7	41.1	37.4	37.4	48.6	41.9	29.7	38.4	35.5	29.9	29.9	32.9	28.0
	<b>65-74 years</b>	35.5	38.5	31.5	38.4	33.3	37.9	46.6	38.8	29.1	33.5	29.4	27.1	27.0	31.5	26.0
	<b>75-99 years</b>	30.3	33.6	26.0	34.4	28.9	30.1	42.1	36.1	23.7	22.0	29.0	19.6	19.3	23.5	22.7

**Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, cohort analysis for 2000-02**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Breast cancer (women)</b>																
<b>One year</b>	<b>No. of patients</b>	20,584	11,868	8,716	36,103	5,053	7,477	2,061	21,512	11,606	8,029	7,448	109,337	100,111	2,797	6,429
	<b>Age-standardised</b>	<b>96.3</b>	<b>96.5</b>	<b>96.0</b>	<b>96.2</b>	<b>95.9</b>	<b>96.5</b>	<b>96.4</b>	<b>96.0</b>	<b>94.3</b>	<b>95.8</b>	<b>98.4</b>	<b>92.4</b>	<b>92.5</b>	<b>95.0</b>	<b>89.8</b>
	<b>15-44 years</b>	98.8	98.6	98.9	98.2	96.9	99.0	97.8	98.2	98.1	97.9	99.3	97.3	97.4	95.8	96.6
	<b>45-54 years</b>	98.5	98.5	98.5	98.2	98.0	98.2	98.4	98.2	98.0	98.6	99.7	97.8	97.9	95.6	97.4
	<b>55-64 years</b>	98.2	98.4	98.0	97.8	98.1	97.8	97.6	97.7	96.1	98.4	99.5	96.8	97.0	95.4	95.0
	<b>65-74 years</b>	96.9	96.5	97.4	97.1	97.2	97.7	96.0	97.0	95.6	95.9	99.1	93.0	93.1	95.8	90.3
	<b>75-99 years</b>	92.7	93.6	91.3	92.5	91.7	93.1	94.7	92.2	89.1	92.0	96.2	85.0	85.0	93.5	80.5
<b>Five years</b>	<b>Age-standardised</b>	<b>87.0</b>	<b>87.4</b>	<b>86.5</b>	<b>86.4</b>	<b>84.9</b>	<b>87.5</b>	<b>83.9</b>	<b>86.6</b>	<b>81.5</b>	<b>83.8</b>	<b>89.3</b>	<b>78.8</b>	<b>78.8</b>	<b>81.6</b>	<b>76.7</b>
	<b>15-44 years</b>	86.7	87.0	86.2	85.8	84.9	88.1	86.5	85.2	85.9	83.6	89.6	81.9	82.0	77.5	82.0
	<b>45-54 years</b>	89.3	89.7	88.9	88.8	86.6	90.0	90.5	88.9	87.0	90.7	92.7	87.2	87.4	79.9	86.4
	<b>55-64 years</b>	90.8	90.8	90.7	88.8	89.2	88.9	86.3	88.9	84.4	89.7	93.0	87.1	87.3	82.0	85.4
	<b>65-74 years</b>	89.2	89.5	88.9	89.2	88.3	89.8	83.7	89.7	83.0	85.2	93.1	79.5	79.6	80.6	77.8
	<b>75-99 years</b>	81.0	81.9	79.8	80.8	77.4	82.9	78.9	81.0	74.5	74.9	81.0	67.3	67.1	84.0	63.4
<b>Conditional 5-year</b>	<b>No. of patients</b>	19,678	11,358	8,320	34,298	4,796	7,110	1,952	20,440	10,749	7,573	7,231	99,737	91,427	2,599	5,711
	<b>Age-standardised</b>	<b>90.3</b>	<b>90.6</b>	<b>90.0</b>	<b>89.8</b>	<b>88.5</b>	<b>90.6</b>	<b>87.0</b>	<b>90.2</b>	<b>86.4</b>	<b>87.3</b>	<b>90.6</b>	<b>85.0</b>	<b>85.0</b>	<b>86.3</b>	<b>85.1</b>
	<b>15-44 years</b>	87.8	88.2	87.2	87.4	87.6	89.0	88.4	86.7	87.5	85.4	90.2	84.2	84.2	80.9	84.8
	<b>45-54 years</b>	90.7	91.0	90.3	90.5	88.3	91.7	92.0	90.5	88.8	92.0	93.0	89.1	89.3	83.6	88.8
	<b>55-64 years</b>	92.4	92.3	92.5	90.8	90.9	90.9	88.4	91.0	87.8	91.1	93.5	89.9	90.0	85.9	89.9
	<b>65-74 years</b>	92.1	92.7	91.2	91.8	90.8	92.0	87.2	92.5	86.8	88.8	94.0	85.4	85.4	84.1	86.2
	<b>75-99 years</b>	87.4	87.4	87.4	87.3	84.4	89.0	83.2	87.9	83.6	81.3	84.2	79.2	78.9	91.4	78.7
<b>Ovarian cancer</b>																
<b>One year</b>	<b>No. of patients</b>	2,070	1,171	899	4,990	552	834	277	3,327	1,867	1,496	-	18,166	16,469	536	1,161
	<b>Age-standardised</b>	<b>71.1</b>	<b>72.8</b>	<b>68.9</b>	<b>73.3</b>	<b>71.0</b>	<b>75.3</b>	<b>74.1</b>	<b>73.1</b>	<b>67.9</b>	<b>74.3</b>	-	<b>62.4</b>	<b>62.6</b>	<b>64.9</b>	<b>60.0</b>
	<b>15-44 years</b>	91.6	91.8	91.2	93.7	91.2	96.6	92.7	93.8	92.6	93.1	-	91.9	91.9	93.8	90.1
	<b>45-54 years</b>	90.2	89.9	90.7	89.4	90.3	89.8	79.8	89.7	84.8	89.6	-	83.5	83.4	81.2	87.1
	<b>55-64 years</b>	84.8	86.6	82.3	82.7	80.0	90.4	82.8	81.3	81.7	90.2	-	77.0	77.0	79.9	75.9
	<b>65-74 years</b>	70.4	71.5	69.1	75.6	78.6	78.6	75.8	74.4	68.4	77.6	-	61.1	61.5	71.0	50.8
	<b>75-99 years</b>	48.0	51.3	43.7	51.8	43.4	48.6	58.6	53.3	43.5	47.5	-	36.5	36.5	33.2	38.0
<b>Five years</b>	<b>Age-standardised</b>	<b>37.1</b>	<b>39.6</b>	<b>34.1</b>	<b>38.4</b>	<b>34.9</b>	<b>37.8</b>	<b>37.1</b>	<b>39.1</b>	<b>33.7</b>	<b>40.2</b>	-	<b>34.3</b>	<b>34.3</b>	<b>37.8</b>	<b>33.8</b>
	<b>15-44 years</b>	66.2	68.1	63.8	73.9	76.4	67.7	85.5	73.7	76.3	74.0	-	77.7	77.6	80.7	76.3
	<b>45-54 years</b>	57.1	59.9	53.2	57.3	62.0	59.4	50.9	56.3	54.0	56.2	-	51.4	51.3	46.9	55.0
	<b>55-64 years</b>	46.5	46.4	46.6	43.1	41.5	48.6	39.1	42.3	39.2	49.1	-	41.0	40.8	45.8	41.1
	<b>65-74 years</b>	31.3	34.8	26.9	34.2	28.8	28.4	36.9	36.1	28.2	38.6	-	28.9	28.8	41.4	24.1
	<b>75-99 years</b>	20.2	23.7	16.2	22.5	14.5	22.5	18.3	24.1	16.3	19.9	-	17.0	17.0	13.7	18.6
<b>Conditional 5-year</b>	<b>No. of patients</b>	1,466	848	618	3,732	410	629	202	2,491	1,296	1,107	-	11,556	10,482	366	708
	<b>Age-standardised</b>	<b>50.4</b>	<b>53.0</b>	<b>47.0</b>	<b>50.9</b>	<b>46.4</b>	<b>49.1</b>	<b>48.1</b>	<b>52.2</b>	<b>47.2</b>	<b>52.2</b>	-	<b>52.8</b>	<b>52.6</b>	<b>55.0</b>	<b>53.9</b>
	<b>15-44 years</b>	72.3	74.1	69.9	78.8	83.8	70.1	92.2	78.6	82.3	79.5	-	84.6	84.5	86.0	84.7
	<b>45-54 years</b>	63.3	66.7	58.6	64.1	68.6	66.1	63.8	62.8	63.6	62.8	-	61.6	61.6	57.8	63.2
	<b>55-64 years</b>	54.8	53.6	56.6	52.1	51.8	53.8	47.2	52.0	47.9	54.4	-	53.2	53.0	57.3	54.2
	<b>65-74 years</b>	44.5	48.7	39.0	45.3	36.7	36.1	48.7	48.5	41.3	49.8	-	47.3	46.8	58.3	47.5
	<b>75-99 years</b>	42.2	46.1	37.0	43.4	33.5	46.3	31.2	45.2	37.4	41.9	-	46.7	46.6	41.3	48.8

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)

**Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, period analysis for 2005-07**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Colorectal cancer (persons)</b>																
One year	No. of patients	37,201	21,111	16,090	56,084	7,192	11,522	3,378	33,992	18,018	15,760	9,950	143,643	130,047	4,540	9,056
	Age-standardised	<b>84.9</b>	<b>84.7</b>	<b>85.1</b>	<b>83.5</b>	<b>80.4</b>	<b>84.3</b>	<b>82.1</b>	<b>83.9</b>	<b>77.7</b>	<b>82.4</b>	<b>83.8</b>	<b>74.7</b>	<b>74.7</b>	<b>76.2</b>	<b>73.6</b>
	15-44 years	89.5	87.1	92.2	92.1	90.2	91.7	90.9	92.8	87.9	89.3	85.1	82.6	82.5	82.6	84.2
	45-54 years	90.4	90.3	90.5	89.1	86.4	90.3	88.3	89.5	86.5	88.6	90.0	83.8	83.9	86.8	80.2
	55-64 years	89.5	89.0	90.3	87.9	84.9	88.6	87.6	88.4	83.6	86.6	86.7	81.5	81.6	82.3	79.6
	65-74 years	86.4	86.7	85.9	84.5	81.3	85.5	81.2	85.0	80.8	83.8	84.5	76.6	76.6	78.4	74.9
	75-99 years	76.4	76.5	76.3	74.5	71.2	75.5	73.8	74.9	63.7	73.3	77.9	61.8	61.8	63.3	62.1
Five years	Age-standardised	<b>65.9</b>	<b>66.4</b>	<b>65.5</b>	<b>63.7</b>	<b>58.3</b>	<b>64.0</b>	<b>63.3</b>	<b>64.9</b>	<b>55.8</b>	<b>62.0</b>	<b>62.6</b>	<b>53.6</b>	<b>53.7</b>	<b>55.2</b>	<b>52.3</b>
	15-44 years	71.2	69.4	73.4	68.8	64.3	68.3	74.1	69.2	62.3	69.6	66.0	59.3	59.1	59.0	62.8
	45-54 years	68.1	68.0	68.3	66.1	66.2	66.2	64.3	66.1	61.6	63.0	63.0	58.1	58.3	53.2	58.4
	55-64 years	68.5	67.2	70.4	67.4	61.1	67.3	67.3	68.8	57.8	63.5	66.2	58.3	58.6	56.7	53.9
	65-74 years	68.2	69.1	67.0	65.6	61.8	66.4	62.9	66.5	58.1	63.6	63.3	55.8	55.7	59.0	54.6
	75-99 years	59.5	61.5	57.0	56.7	47.8	56.9	57.4	58.7	47.9	57.1	58.3	44.5	44.4	50.1	43.8
Conditional 5-year	No. of patients	25,520	14,424	11,096	38,196	4,832	7,908	2,240	23,216	11,397	10,566	6,877	88,269	80,040	2,763	5,466
	Age-standardised	<b>77.7</b>	<b>78.4</b>	<b>76.8</b>	<b>76.4</b>	<b>72.3</b>	<b>75.9</b>	<b>77.1</b>	<b>77.4</b>	<b>72.1</b>	<b>75.4</b>	<b>74.8</b>	<b>71.8</b>	<b>71.8</b>	<b>73.0</b>	<b>71.1</b>
	15-44 years	79.6	79.6	79.6	74.6	71.2	74.5	81.5	74.6	70.9	77.9	77.5	71.8	71.6	71.4	74.6
	45-54 years	75.4	75.4	75.4	74.1	76.7	73.3	72.9	73.8	71.2	71.0	69.9	69.4	69.5	61.3	72.7
	55-64 years	76.5	75.5	78.0	76.7	72.0	76.0	76.8	77.8	69.1	73.3	76.4	71.5	71.9	68.9	67.6
	65-74 years	79.0	79.7	78.0	77.7	76.0	77.6	77.4	78.2	71.9	75.9	74.9	72.8	72.7	75.3	72.9
	75-99 years	77.8	80.4	74.6	76.1	67.2	75.3	77.8	78.4	75.2	77.9	74.8	72.0	71.9	79.2	70.5
<b>Lung cancer (persons)</b>																
One year	No. of patients	21,101	12,113	8,988	49,678	6,536	10,321	3,186	29,635	15,419	9,146	5,188	120,796	109,526	3,494	7,776
	Age-standardised	<b>42.8</b>	<b>42.9</b>	<b>42.7</b>	<b>43.1</b>	<b>41.5</b>	<b>43.0</b>	<b>42.7</b>	<b>43.4</b>	<b>34.9</b>	<b>39.2</b>	<b>43.6</b>	<b>29.7</b>	<b>29.7</b>	<b>30.6</b>	<b>28.5</b>
	15-44 years	62.2	61.1	63.7	58.0	59.6	61.7	61.6	56.6	41.6	54.0	64.1	43.6	43.8	45.2	38.3
	45-54 years	48.3	48.6	48.0	47.6	44.6	47.8	48.1	47.9	45.0	47.6	44.3	36.2	36.1	37.4	36.9
	55-64 years	49.7	50.3	48.7	46.8	44.1	46.1	45.4	47.6	40.4	44.0	46.4	34.4	34.5	33.9	32.7
	65-74 years	42.5	42.8	42.0	43.0	40.7	43.2	40.8	43.6	36.4	40.7	43.8	29.8	29.9	30.1	28.5
	75-99 years	30.8	30.4	31.3	34.7	34.7	33.9	35.7	34.7	23.4	26.9	35.8	19.7	19.7	22.1	19.3
Five years	Age-standardised	<b>17.0</b>	<b>17.6</b>	<b>16.2</b>	<b>18.4</b>	<b>15.1</b>	<b>17.7</b>	<b>20.1</b>	<b>19.1</b>	<b>10.9</b>	<b>14.4</b>	<b>16.3</b>	<b>8.8</b>	<b>8.7</b>	<b>11.0</b>	<b>9.0</b>
	15-44 years	34.1	32.4	36.3	31.8	27.1	30.4	20.4	33.6	19.2	35.1	38.1	20.4	20.1	30.5	18.1
	45-54 years	19.0	20.4	17.2	21.6	19.7	20.6	21.3	22.3	15.5	19.1	15.7	12.0	11.8	14.6	13.9
	55-64 years	20.2	20.6	19.7	20.8	17.9	20.4	23.8	21.2	12.6	16.2	16.9	10.4	10.3	12.0	11.1
	65-74 years	16.4	17.6	14.8	17.7	13.6	17.6	20.7	18.3	10.6	13.5	15.4	8.1	8.1	9.5	7.6
	75-99 years	10.0	10.4	9.5	12.8	9.5	11.4	16.0	13.6	5.9	7.1	11.8	4.1	4.1	5.4	4.5
Conditional 5-year	No. of patients	7,958	4,566	3,392	19,163	2,447	3,806	1,276	11,634	4,995	3,206	1,993	33,157	30,105	993	2,059
	Age-standardised	<b>38.6</b>	<b>40.1</b>	<b>36.6</b>	<b>42.1</b>	<b>35.4</b>	<b>40.3</b>	<b>47.4</b>	<b>43.5</b>	<b>30.3</b>	<b>35.0</b>	<b>36.5</b>	<b>28.2</b>	<b>27.9</b>	<b>33.8</b>	<b>30.2</b>
	15-44 years	54.9	53.1	57.0	54.7	45.5	49.3	33.1	59.3	46.2	64.9	59.4	46.8	45.9	67.5	47.3
	45-54 years	39.3	42.0	35.9	45.5	44.2	43.1	44.2	46.6	34.4	40.0	35.4	33.1	32.6	39.0	37.5
	55-64 years	40.7	41.0	40.5	44.4	40.5	44.2	52.6	44.5	31.1	36.7	36.4	30.3	29.9	35.3	33.8
	65-74 years	38.6	41.1	35.2	41.2	33.4	40.6	50.7	42.0	29.1	33.1	35.0	27.2	27.1	31.5	26.7
	75-99 years	32.6	34.4	30.4	36.8	27.5	33.6	44.9	39.0	25.3	26.4	33.0	21.1	20.8	24.5	23.6

**Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer and jurisdiction, period analysis for 2005-07**

	Australia			Canada					Denmark	Norway	Swedish regions	United Kingdom				
	Australian registries	New South Wales	Victoria	Canadian registries	Alberta	British Columbia	Manitoba	Ontario				UK registries	England	Northern Ireland	Wales	
<b>Breast cancer (women)</b>																
One year	No. of patients	35,988	20,736	15,252	64,756	9,012	13,349	3,660	38,735	20,347	14,121	13,416	197,184	180,426	5,312	11,446
	Age-standardised	<b>96.7</b>	<b>96.5</b>	<b>97.1</b>	<b>96.3</b>	<b>95.9</b>	<b>97.1</b>	<b>96.7</b>	<b>96.1</b>	<b>95.0</b>	<b>96.6</b>	<b>98.0</b>	<b>94.2</b>	<b>94.3</b>	<b>95.0</b>	<b>93.4</b>
	15-44 years	98.7	98.6	98.7	98.5	98.1	98.8	96.6	98.6	99.1	98.1	99.4	98.2	98.2	97.7	97.9
	45-54 years	98.8	98.5	99.2	98.2	98.2	99.1	98.6	97.9	98.2	99.3	99.1	98.2	98.2	98.0	98.1
	55-64 years	98.7	98.6	98.7	97.7	97.4	98.0	97.3	97.7	97.9	98.5	99.1	97.5	97.5	98.7	97.4
	65-74 years	97.5	97.7	97.4	97.2	97.3	97.1	98.1	97.1	95.9	97.8	98.1	96.1	96.1	96.1	95.4
	75-99 years	93.1	92.2	94.3	93.1	91.7	95.1	94.2	92.6	89.5	92.3	96.3	87.2	87.2	89.2	85.0
Five years	Age-standardised	<b>88.1</b>	<b>87.8</b>	<b>88.5</b>	<b>86.3</b>	<b>82.6</b>	<b>89.1</b>	<b>86.8</b>	<b>86.4</b>	<b>82.4</b>	<b>85.5</b>	<b>88.5</b>	<b>81.6</b>	<b>81.6</b>	<b>84.1</b>	<b>81.0</b>
	15-44 years	87.9	87.9	87.9	87.0	89.2	87.3	83.5	86.5	87.4	85.1	91.4	84.1	84.1	83.4	83.9
	45-54 years	90.5	90.5	90.4	89.4	89.2	90.5	91.6	88.9	88.5	91.4	91.9	88.3	88.4	85.5	89.0
	55-64 years	91.5	92.0	90.8	89.0	88.0	89.9	88.4	89.0	86.6	91.6	92.1	88.8	88.8	87.3	88.9
	65-74 years	90.6	91.2	89.7	88.8	86.1	90.8	89.4	88.8	83.8	88.6	90.5	84.5	84.4	86.5	84.1
	75-99 years	82.1	79.9	84.9	80.3	70.3	86.7	81.9	80.7	73.9	75.1	81.4	69.8	69.6	78.7	67.5
Conditional 5-year	No. of patients	27,975	16,137	11,838	49,797	6,953	10,256	2,807	29,781	15,582	11,023	10,496	150,852	138,152	4,026	8,674
	Age-standardised	<b>91.0</b>	<b>90.9</b>	<b>91.2</b>	<b>89.6</b>	<b>86.0</b>	<b>91.8</b>	<b>89.7</b>	<b>89.8</b>	<b>86.6</b>	<b>88.4</b>	<b>90.2</b>	<b>86.4</b>	<b>86.4</b>	<b>88.9</b>	<b>86.4</b>
	15-44 years	89.1	89.1	89.1	88.3	90.9	88.4	86.4	87.8	88.2	86.7	91.9	85.6	85.6	85.3	85.7
	45-54 years	91.6	92.0	91.1	91.1	90.9	91.4	92.9	90.9	90.1	92.1	92.7	90.0	90.0	87.2	90.7
	55-64 years	92.7	93.2	92.0	91.1	90.4	91.8	90.9	91.1	88.5	92.9	93.0	91.0	91.1	88.5	91.2
	65-74 years	92.8	93.4	92.1	91.4	88.5	93.5	91.1	91.5	87.3	90.7	92.3	87.9	87.8	90.0	88.2
	75-99 years	88.2	86.6	90.3	86.2	76.7	91.2	86.9	87.1	82.6	81.3	84.5	80.1	79.8	89.8	79.4
<b>Ovarian cancer</b>																
One year	No. of patients	3,539	2,013	1,526	8,313	863	1,372	434	5,644	2,690	2,192	-	26,877	24,355	825	1,697
	Age-standardised	<b>73.5</b>	<b>73.3</b>	<b>73.7</b>	<b>75.2</b>	<b>69.7</b>	<b>77.6</b>	<b>68.0</b>	<b>75.9</b>	<b>70.6</b>	<b>75.2</b>	-	<b>65.0</b>	<b>65.4</b>	<b>63.9</b>	<b>60.5</b>
	15-44 years	91.8	92.1	91.3	92.6	86.0	94.0	90.0	93.3	92.0	92.5	-	93.0	93.0	97.3	90.0
	45-54 years	91.9	93.7	88.9	90.4	95.4	91.8	82.1	89.7	91.9	88.5	-	83.8	83.9	87.2	80.5
	55-64 years	86.7	87.5	85.6	84.9	83.0	88.2	79.1	84.7	80.6	89.8	-	79.1	79.8	71.3	73.9
	65-74 years	77.9	77.5	78.3	79.3	69.0	83.8	72.9	80.0	72.4	80.1	-	65.9	66.1	64.3	62.9
	75-99 years	46.6	44.9	49.1	52.8	45.4	53.1	43.1	54.8	46.7	49.0	-	38.5	38.9	39.9	32.2
Five years	Age-standardised	<b>37.5</b>	<b>39.9</b>	<b>34.2</b>	<b>41.9</b>	<b>36.9</b>	<b>44.1</b>	<b>28.8</b>	<b>43.2</b>	<b>36.1</b>	<b>39.7</b>	-	<b>36.4</b>	<b>36.4</b>	<b>36.5</b>	<b>36.3</b>
	15-44 years	69.8	72.8	66.1	75.8	65.6	74.4	72.1	77.8	72.9	76.1	-	79.4	79.1	86.3	80.2
	45-54 years	58.2	62.1	52.5	60.7	64.6	62.6	47.2	60.5	56.0	56.9	-	54.0	53.8	53.1	57.1
	55-64 years	41.8	42.1	41.1	47.3	42.0	47.8	31.1	49.3	40.4	46.9	-	42.2	42.2	34.3	45.5
	65-74 years	38.6	41.1	35.2	38.9	32.7	43.3	28.6	39.6	34.5	38.4	-	32.4	32.5	34.1	29.8
	75-99 years	16.6	19.8	12.3	24.7	18.7	26.8	9.2	26.6	17.1	19.4	-	18.0	18.0	21.7	16.4
Conditional 5-year	No. of patients	2,303	1,312	991	5,466	563	915	274	3,714	1,720	1,467	-	16,350	14,825	532	993
	Age-standardised	<b>48.7</b>	<b>52.7</b>	<b>43.5</b>	<b>54.4</b>	<b>50.8</b>	<b>55.8</b>	<b>39.1</b>	<b>55.7</b>	<b>48.8</b>	<b>50.9</b>	-	<b>53.8</b>	<b>53.5</b>	<b>55.7</b>	<b>57.4</b>
	15-44 years	76.0	79.1	72.3	81.9	76.3	79.2	80.1	83.4	79.3	82.2	-	85.4	85.0	88.7	89.1
	45-54 years	63.4	66.3	59.0	67.1	67.7	68.3	57.4	67.5	61.0	64.3	-	64.4	64.1	60.9	71.0
	55-64 years	48.1	48.1	48.0	55.6	50.7	54.2	39.3	58.2	50.1	52.2	-	53.3	53.0	48.2	61.6
	65-74 years	49.6	53.0	45.0	49.0	47.3	51.7	39.3	49.5	47.6	48.0	-	49.2	49.2	53.0	47.4
	75-99 years	35.7	44.1	25.1	46.8	41.2	50.5	21.3	48.6	36.6	39.7	-	46.7	46.3	54.3	51.0

Some age-standardised estimates arise from imputed age-specific estimates (see text)

Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)

Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in *The Lancet* article)

**Table 15: Age-standardised (world) annual incidence and mortality rates per 100,000 in 2000, with mortality-incidence ratios: cancer and country**

	Colorectum	Lung			Breast	Ovary
	Persons	Males	Females	Persons	Females	
<b>Incidence*</b>						
Australia	40.3	38.2	17.5	27.0	84.4	8.0
Canada <sup>1</sup>	35.6	47.9	31.6	38.9	80.7	9.4
Denmark	33.9	46.2	31.6	37.9	83.7	13.2
Norway	36.1	35.5	19.2	26.4	71.0	12.8
Sweden	26.3	20.9	14.5	17.3	78.9	10.5
UK <sup>2</sup>	29.3	43.8	22.6	31.9	82.1	11.9
<b>Mortality</b>						
Australia	14.2	32.1	13.6	22.1	16.6	4.8
Canada	12.2	44.5	24.8	33.5	18.3	5.4
Denmark	17.8	42.6	27.6	34.1	25.2	8.7
Norway	16.0	31.2	15.3	22.4	16.8	7.1
Sweden	11.5	21.0	13.4	16.7	15.8	6.7
UK <sup>3</sup>	12.7	39.5	19.9	28.4	21.5	7.7
<b>Mortality/Incidence ratios</b>						
Australia	0.35	0.84	0.78	0.82	0.20	0.60
Canada <sup>1</sup>	0.34	0.93	0.78	0.86	0.23	0.57
Denmark	0.53	0.92	0.87	0.90	0.30	0.66
Norway	0.44	0.88	0.80	0.85	0.24	0.55
Sweden	0.44	1.00	0.92	0.97	0.20	0.64
UK	0.43	0.90	0.88	0.89	0.26	0.65

Source for incidence rates around 2000 (1998-2002): Cancer Incidence in Five Continents, vol IX<sup>12</sup>

Source for mortality rates for 2000: WHO mortality databank

<sup>1</sup> Excludes Quebec; <sup>2</sup> England and Northern Ireland only; <sup>3</sup> England and Wales only

\* Colorectal cancer includes cancers of the anus and anal canal; lung cancer includes cancers of the trachea.

